Obstetrics and gynaecology

Telomere length is longer in women with late maternal age. PMID:
Learn more Learn more
Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women; a multicentre randomised placebo controlled trial. PMID: 28109045

Tasma ML, Louwerse M, Hehenkamp WJ, Geomini PM, Bongers MY, Veersema S, van Kesteren PJ, Tromp E, Huirne JA, Graziosi GC.BJOG. 2017 Jan 21.doi: 10.1111/1471-0528.14567. [Epub ahead of print]

Learn more Learn more
Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. PMID: 28089571

Pinola P, Puukka K, Piltonen TT, Puurunen J, Vanky E, Sundström-Poromaa I, Stener-Victorin E, Lindén Hirschberg A, Ravn P, Skovsager Andersen M, Glintborg D, Mellembakken JR, Ruokonen A, Tapanainen JS, Morin-Papunen LC.Fertil Steril. 2017 Jan 12. pii: S0015-0282(16)63089-3.doi: 10.1016/j.fertnstert.2016.12.017. [Epub ahead of print]

Learn more Learn more
A national population-based cohort study of urethral injection therapy for female stress and mixed urinary incontinence: the Danish Urogynaecological Database, 2007-2011. PMID: 28210793

Hansen MF, Lose G, Kesmodel US, Gradel KO.Int Urogynecol J. 2017 Feb 16.doi: 10.1007/s00192-017-3265-z. [Epub ahead of print]

Learn more Learn more
Obstetrics and gynaecology  PMID: 28212118

Role of chronic exercise on pelvic floor support and function.Shaw JM, Nygaard IE.Curr Opin Urol. 2017 Feb 16.doi: 10.1097/MOU.0000000000000390. [Epub ahead of print]

Learn more Learn more
A national population-based cohort study of urethral injection therapy for female stress and mixed urinary incontinence: the Danish Urogynaecological Database, 2007-2011. PMID: 28210793

Hansen MF, Lose G, Kesmodel US, Gradel KO.Int Urogynecol J. 2017 Feb 16.doi: 10.1007/s00192-017-3265-z. [Epub ahead of print]

Learn more Learn more
Role of chronic exercise on pelvic floor support and function. PMID: 28212118

Shaw JM, Nygaard IE.Curr Opin Urol. 2017 Feb 16.doi: 10.1097/MOU.0000000000000390. [Epub ahead of print]

Learn more Learn more
Can incontinence be cured? A systematic review of cure rates. PMID: 28335792

Riemsma R, Hagen S, Kirschner-Hermanns R, Norton C, Wijk H, Andersson KE, Chapple C, Spinks J, Wagg A, Hutt E, Misso K, Deshpande S, Kleijnen J, Milsom I.BMC Med. 2017 Mar 24;15(1):63.doi: 10.1186/s12916-017-0828-2.

Learn more Learn more
Ovarian hormones and obesity. PMID: 28333235

Leeners B, Geary N, Tobler PN, Asarian L.Hum Reprod Update. 2017 Mar 2:1-22.doi: 10.1093/humupd/dmw045. [Epub ahead of print]

Learn more Learn more
Racial and Ethnic Differences in the Prevalence of Metabolic Syndrome and its Components of Metabolic Syndrome in Women with Polycystic Ovary Syndrome (PCOS): A Regional Cross-Sectional Study. PMID: 28400308

Chan JL, Kar S, Vanky E, Morin-Papunen L, Piltonen T, Puurunen J, Tapaniennen JS, Rosa Maciel GA, Hayashida SA, Saores JM Jr, Baracat EC, Mellembakkam JR, Dokras A.Am J Obstet Gynecol. 2017 Apr 8. pii: S0002-9378(17)30508-2. doi: 10.1016/j.ajog.2017.04.007. [Epub ahead of print]

Learn more Learn more
Neurodevelopmental Effects of Antiepileptic Drugs. PMID: 28424947

Kellogg M, Meador KJ.Neurochem Res. 2017 Apr 19. doi: 10.1007/s11064-017-2262-4. [Epub ahead of print]

Learn more Learn more
Is the delivery of a quality improvement education programme in obstetrics and gynaecology for final year medical students feasible and still effective in a shortened time frame? PMID: 28549464

Kool B, Wise MR, Peiris-John R, Sadler L, Mahony F, Wells S.BMC Med Educ. 2017 May 26;17(1):91.doi: 10.1186/s12909-017-0927-y.

Learn more Learn more
Early pregnancy vaginal microbiome trends and preterm birth. PMID: 28549981

Stout MJ, Zhou Y, Wylie KM, Tarr PI, Macones GA, Tuuli MG.Am J Obstet Gynecol. 2017 May 23.pii: S0002-9378(17)30641-5. doi: 10.1016/j.ajog.2017.05.030. [Epub ahead of print]

Learn more Learn more
Antibiotic prophylaxis for elective hysterectomy. PMID: 28625021

Ayeleke RO, Mourad S, Marjoribanks J, Calis KA, Jordan V.Cochrane Database Syst Rev. 2017 Jun 18;6:CD004637.doi: 10.1002/14651858.CD004637.pub2. [Epub ahead of print] Review.

Learn more Learn more
Adverse childhood or adult experiences and risk of bilateral oophorectomy: a population-based case-control study. PMID: 28592582

Gazzuola Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Stewart EA, Rocca WA.BMJ Open. 2017 Jun 7;7(5):e016045.doi: 10.1136/bmjopen-2017-016045.

Learn more Learn more
Hysterectomy technique and risk of pelvic organ prolapse repair: a Danish nationwide cohort study. PMID: 28733916

Lykke R, Løwenstein E, Blaakær J, Gimbel H.Arch Gynecol Obstet. 2017 Jul 21.doi: 10.1007/s00404-017-4470-1. [Epub ahead of print]

Learn more Learn more
Feasibility of Prophylactic Salpingectomy During Vaginal Hysterectomy. PMID: 28734829

Antosh DD, High R, Brown HW, Oliphant SS, Abed H, Philip N, Grimes CL.Am J Obstet Gynecol. 2017 Jul 19.pii: S0002-9378(17)30859-1. doi: 10.1016/j.ajog.2017.07.017. [Epub ahead of print]

Learn more Learn more
Optimal Order of Successive Office Hysteroscopy and Endometrial Biopsy for the Evaluation of Abnormal Uterine Bleeding: A Randomized Controlled Trial. PMID: 28796688

Sarkar P, Mikhail E, Schickler R, Plosker S, Imudia AN.Obstet Gynecol. 2017 Aug 4. doi: 10.1097/AOG.0000000000002202. [Epub ahead of print]

Learn more Learn more
Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome? PMID: 28814559

Copp T, Jansen J, Doust J, Mol BW, Dokras A, McCaffery K.BMJ. 2017 Aug 16;358:j3694. doi: 10.1136/bmj.j3694.

Learn more Learn more
Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. PMID: 28923465

Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, et al; CONCEPTT Collaborative Group.Lancet. 2017 Sep 14. pii: S0140-6736(17)32400-5.doi: 10.1016/S0140-6736(17)32400-5. [Epub ahead of print]

Learn more Learn more
The Association of Maternal Asthma and Early Pregnancy Vitamin D with Risk of Preeclampsia: An Observation From Vitamin D Antenatal Asthma Reduction Trial (VDAART). PMID: 28923490

Mirzakhani H, Carey VJ, McElrath TF, Laranjo N, O’Connor G,et al.J Allergy Clin Immunol Pract. 2017 Sep 8.pii: S2213-2198(17)30543-3. doi: 10.1016/j.jaip.2017.07.018. [Epub ahead of print]

Learn more Learn more
Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. PMID: 28986093

Matsuo K, Machida H, Frimer M, Marcus JZ, Pejovic T, Roman LD, Wright JD.Gynecol Oncol. 2017 Oct 3.pii: S0090-8258(17)31351-3. doi: 10.1016/j.ygyno.2017.09.027. [Epub ahead of print]

Learn more Learn more
The ethics of maternal-fetal surgery. PMID: 28986215

Chervenak FA, McCullough LB.Semin Fetal Neonatal Med. 2017 Oct 3.pii: S1744-165X(17)30110-5. doi: 10.1016/j.siny.2017.09.008. [Epub ahead of print] Review.

Learn more Learn more
Impact of Pelvic Pain and Endometriosis on Patient-Reported Outcomes and Experiences of Benign Hysterectomy: A Study from the Swedish National Register for Gynecological Surgery PMID: 29148910

.Grundström H, Alehagen S, Berterö C, Kjølhede P.J Womens Health (Larchmt). 2017 Nov 17.doi: 10.1089/jwh.2017.6546. [Epub ahead of print]

Learn more Learn more
Sleep and Dietary Patterns in Pregnancy: Findings from the GUSTO Cohort. PMID: 29149071

van Lee L, Chia AR, Loy SL, Colega M, Tham EKH, Cai S, Yap F, Godfrey KM, Teoh OH, Goh D, Tan KH, Chong YS, Broekman BFP, Chong MFF.Int J Environ Res Public Health. 2017 Nov 17;14(11).pii: E1409. doi: 10.3390/ijerph14111409.

Learn more Learn more
Spectrum Of Symptoms In Women Diagnosed With Endometriosis During Adolescence Versus Adulthood. PMID: 29247637

DiVasta AD, Vitonis AF, Laufer MR, Missmer SA.Am J Obstet Gynecol. 2017 Dec 13.pii: S0002-9378(17)32482-1. doi: 10.1016/j.ajog.2017.12.007. [Epub ahead of print]

Learn more Learn more
Bisphenol and phthalate concentrations and its determinants among pregnant women in a population-based cohort in the Netherlands, 2004-5. PMID: 29245124

Philips EM, Jaddoe VWV, Asimakopoulos AG, Kannan K, Steegers EAP, Santos S, Trasande L.Environ Res. 2017 Dec 12;161:562-572.doi: 10.1016/j.envres.2017.11.051. [Epub ahead of print]

Learn more Learn more
Preventing Mesh Pore Collapse by Designing Mesh Pores with Auxetic Geometries: A Comprehensive Evaluation via Computational Modeling. PMID: 29350744

Knight K, Moalli P, Abramowitch SD.J Biomech Eng. 2018 Jan 19.doi: 10.1115/1.4039058. [Epub ahead of print]

Learn more Learn more
Ebola Infection in Pregnancy: A Global Perspective and Lessons Learned. PMID: 29351152

Haddad LB, Horton J, Ribner BS, Jamieson DJ.Clin Obstet Gynecol. 2018 Mar;61(1):186-196.doi: 10.1097/GRF.0000000000000332.

Learn more Learn more
Surgical Outcomes After Apical Repair for Vault Compared With Uterovaginal Prolapse. PMID: 29420409

Rogers RG, Nolen TL, Weidner AC, Richter HE, Jelovsek JE, Shepherd JP, Harvie HS, Brubaker L, Menefee SA, Myers D, Hsu Y, Schaffer JI, Wallace D, Meikle SF; Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network.Obstet Gynecol. 2018 Feb 5.doi: 10.1097/AOG.0000000000002492. [Epub ahead of print]

Learn more Learn more
Adherence to the Mediterranean diet and IVF success rate among non-obese women attempting fertility. PMID: 29390148

Karayiannis D, Kontogianni MD, Mendorou C, Mastrominas M, Yiannakouris N.Hum Reprod. 2018 Jan 30.doi: 10.1093/humrep/dey003. [Epub ahead of print]

Learn more Learn more
It is the first birth that does the damage: a cross-sectional study 20 years after delivery. PMID: 2956451

Kamisan Atan I, Lin S, Dietz HP, Herbison P, Wilson PD; ProLong Study Group.Int Urogynecol J. 2018 Mar 21.doi: 10.1007/s00192-018-3616-4. [Epub ahead of print]

Learn more Learn more
Long-term follow-up of bulking agents for stress urinary incontinence in older patients. PMID: 29557846

Plotti F, Montera R, Terranova C, Luvero D, Marrocco F, Miranda A, Gatti A, De Cicco Nardone C, Angioli R, Scaletta G.Menopause. 2018 Mar 19.doi: 10.1097/GME.0000000000001068. [Epub ahead of print]

Learn more Learn more
Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation. PMID: 29641835

Multinu F, Casarin J, Hanson KT, Angioni S, Mariani A, Habermann EB, Laughlin-Tommaso SK.JAMA Surg. 2018 Apr 11:e180141.doi: 10.1001/jamasurg.2018.0141. [Epub ahead of print]

Learn more Learn more
Prevalence of urinary incontinence in female athletes: a systematic review with meta-analysis. PMID: 29654349

Teixeira RV, Colla C, Sbruzzi G, Mallmann A, Paiva LL.Int Urogynecol J. 2018 Apr 13.doi: 10.1007/s00192-018-3651-1. [Epub ahead of print] Review.

Learn more Learn more
Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation. PMID: 29641835

Multinu F, Casarin J, Hanson KT, Angioni S, Mariani A, Habermann EB, Laughlin-Tommaso SK.JAMA Surg. 2018 Apr 11:e180141.doi: 10.1001/jamasurg.2018.0141. [Epub ahead of print]

Learn more Learn more
Prevalence of urinary incontinence in female athletes: a systematic review with meta-analysis. PMID: 29654349

Teixeira RV, Colla C, Sbruzzi G, Mallmann A, Paiva LL.Int Urogynecol J. 2018 Apr 13.doi: 10.1007/s00192-018-3651-1. [Epub ahead of print] Review.

Learn more Learn more
Hypertensive disorders of pregnancy and subsequent maternal cardiovascular health. PMID: 29779204

Bergen NE, Schalekamp-Timmermans S, Roos-Hesselink J, Roeters van Lennep JE, Jaddoe VVW, Steegers EAP.Eur J Epidemiol. 2018 May 19. doi: 10.1007/s10654-018-0400-1. [Epub ahead of print]

Learn more Learn more
Elucidating the genetic architecture of reproductive ageing in the Japanese population. PMID: 29773799

Horikoshi M, Day FR, Akiyama M, Hirata M, Kamatani Y, Matsuda K, Ishigaki K, Kanai M, Wright H, Toro CA, Ojeda SR, Lomniczi A, Kubo M, Ong KK, Perry JRB.Nat Commun. 2018 May 17;9(1):1977. doi: 10.1038/s41467-018-04398-z.

Learn more Learn more
ICSI does not increase the cumulative live birth rate in non-male factor infertility. PMID: 29897449

Li Z, Wang AY, Bowman M, Hammarberg K, Farquhar C, Johnson L, Safi N, Sullivan EA.Hum Reprod. 2018 Jun 12. doi: 10.1093/humrep/dey118. [Epub ahead of print]

Learn more Learn more
Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. PMID: 29896812

Tan MY, Syngelaki A, Poon LC, Rolnik DL, O’Gorman N, Delgado JL, Akolekar R, Konstantinidou L, Tsavdaridou M, Galeva S, Ajdacka U, Molina FS, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright A, Wright D, Nicolaides KH.Ultrasound Obstet Gynecol. 2018 Jun 13. doi: 10.1002/uog.19112. [Epub ahead of print]

Learn more Learn more
Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy. PMID: 30020964

Stringer EM, Kendall MA, Lockman S, Campbell TB, Nielsen-Saines K, Sawe F, Cu-Uvin S, Wu X, Currier JS.PLoS One. 2018 Jul 18;13(7):e0199555. doi: 10.1371/journal.pone.0199555. eCollection 2018.

Learn more Learn more
Postmenopausal hormone therapy is accompanied by elevated risk for uterine prolapse. PMID: 29994974

Rahkola-Soisalo P, Savolainen-Peltonen H, Gissler M, Hoti F, Vattulainen P, Ylikorkala O, Mikkola TS.Menopause. 2018 Jul 9. doi: 10.1097/GME.0000000000001173. [Epub ahead of print]

Learn more Learn more
The association between the number of oocytes retrieved for IVF, perinatal outcome and obstetric complications. PMID: 30124838

Magnusson Å, Wennerholm UB, Källén K, Petzold M, Thurin-Kjellberg A, Bergh C.Hum Reprod. 2018 Aug 16. doi: 10.1093/humrep/dey266. [Epub ahead of print]

Learn more Learn more
Intrauterine multi-metal exposure is associated with reduced fetal growth through modulation of the placental gene network. PMID: 30125854

Deyssenroth MA, Gennings C, Liu SH, Peng S, Hao K, Lambertini L, Jackson BP, Karagas MR, Marsit CJ, Chen J.Environ Int. 2018 Aug 16;120:373-381. doi: 10.1016/j.envint.2018.08.010. [Epub ahead of print]

Learn more Learn more
Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. PMID: 30209050

Wen SW, White RR, Rybak N, Gaudet LM, Robson S, Hague W, Simms-Stewart D, Carroli G, Smith G, Fraser WD, Wells G, Davidge ST, Kingdom J, Coyle D, Fergusson D, Corsi DJ, Champagne J, Sabri E, Ramsay T, Mol BWJ, Oudijk MA, Walker MC; FACT Collaborating Group.BMJ. 2018 Sep 12;362:k3478. doi: 10.1136/bmj.k3478.

Learn more Learn more
Do female elite athletes experience more complicated childbirth than non-athletes? A case-control study. PMID: 30228171

Sigurdardottir T, Steingrimsdottir T, Geirsson RT, Halldorsson TI, Aspelund T, Bø K.Br J Sports Med. 2018 Sep 18. pii: bjsports-2018-099447. doi: 10.1136/bjsports-2018-099447. [Epub ahead of print]

Learn more Learn more
Pre-eclampsia and risk of dementia later in life: nationwide cohort study. PMID: 30333106

Basit S, Wohlfahrt J, Boyd HA.BMJ. 2018 Oct 17;363:k4109. doi: 10.1136/bmj.k4109.

Learn more Learn more
Short-term and long-term effects of caesarean section on the health of women and children. PMID: 30322585

Sandall J, Tribe RM, Avery L, Mola G, Visser GH, Homer CS, Gibbons D, Kelly NM, Kennedy HP, Kidanto H, Taylor P, Temmerman M.Lancet. 2018 Oct 13;392(10155):1349-1357. doi: 10.1016/S0140-6736(18)31930-5. Review.

Learn more Learn more
Soy-based infant formula feeding and menstrual pain in a cohort of women aged 23-35 years. PMID: 30412246

Upson K, Adgent MA, Wegienka G, Baird DD.Hum Reprod. 2018 Nov 9. doi: 10.1093/humrep/dey303. [Epub ahead of print]

Learn more Learn more
Association of Prenatal Exposure to Air Pollution With Autism Spectrum Disorder. PMID: 30452514

Pagalan L, Bickford C, Weikum W, Lanphear B, Brauer M, Lanphear N, Hanley GE, Oberlander TF, Winters M.JAMA Pediatr. 2018 Nov 19. doi: 10.1001/jamapediatrics.2018.3101. [Epub ahead of print]

Learn more Learn more
Association of phthalates, parabens and phenols found in personal care products with pubertal timing in girls and boys. PMID: 30517665

Harley KG, Berger KP, Kogut K, Parra K, Lustig RH, Greenspan LC, Calafat AM, Ye X, Eskenazi B.Hum Reprod. 2019 Jan 1;34(1):109-117. doi: 10.1093/humrep/dey337.

Learn more Learn more
A Mediterranean Diet with an Enhanced Consumption of Extra Virgin Olive Oil and Pistachios Improves Pregnancy Outcomes in Women Without Gestational Diabetes Mellitus: A Sub-Analysis of the St. Carlos Gestational Diabetes Mellitus Prevention Study. PMID: 30554220

Assaf-Balut C, García de la Torre N, Duran A, Fuentes M, Bordiú E, Del Valle L, Familiar C, Valerio J, Jiménez I, Herraiz MA, Izquierdo N, Torrejon MJ, Cuadrado MÁ, Ortega I, Illana FJ, Runkle I, de Miguel P, Moraga I, Montañez C, Barabash A, Cuesta M, Rubio MA, Calle-Pascual AL.Ann Nutr Metab. 2018 Dec 14;74(1):69-79. doi: 10.1159/000495793. [Epub ahead of print]

Learn more Learn more
Developmental origins of endometriosis: a Swedish cohort study. PMID: 30661033

Gao M, Allebeck P, Mishra GD, Koupil I.J Epidemiol Community Health. 2019 Jan 19. pii: jech-2018-211811. doi: 10.1136/jech-2018-211811. [Epub ahead of print]

Learn more Learn more
Mitochondria as a tool for oocyte rejuvenation. PMID: 30611551

Labarta E, de Los Santos MJ, Escribá MJ, Pellicer A, Herraiz S.Fertil Steril. 2019 Jan 2. pii: S0015-0282(18)32162-9. doi: 10.1016/j.fertnstert.2018.10.036. [Epub ahead of print] Review.

Learn more Learn more
Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women with Polycystic Ovary Syndrome. PMID: 30786001

Gorsic LK, Dapas M, Legro RS, Hayes MG, Urbanek M.J Clin Endocrinol Metab. 2019 Feb 20. pii: jc.2018-02178. doi: 10.1210/jc.2018-02178. [Epub ahead of print]

Learn more Learn more
Delivery-associated sepsis: trends in prevalence and mortality. PMID: 30786257

Kendle AM, Salemi JL, Tanner JP, Louis JM.Am J Obstet Gynecol. 2019 Feb 13. pii: S0002-9378(19)30325-4. doi: 10.1016/j.ajog.2019.02.002. [Epub ahead of print]

Learn more Learn more
Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women with Polycystic Ovary Syndrome. PMID: 30786001

Gorsic LK, Dapas M, Legro RS, Hayes MG, Urbanek M.J Clin Endocrinol Metab. 2019 Feb 20. pii: jc.2018-02178. doi: 10.1210/jc.2018-02178. [Epub ahead of print]

Learn more Learn more
Delivery-associated sepsis: trends in prevalence and mortality. PMID: 30786257

Kendle AM, Salemi JL, Tanner JP, Louis JM.Am J Obstet Gynecol. 2019 Feb 13. pii: S0002-9378(19)30325-4. doi: 10.1016/j.ajog.2019.02.002. [Epub ahead of print]

Learn more Learn more
Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis. PMID: 30867561

Katsigianni M, Karageorgiou V, Lambrinoudaki I, Siristatidis C.Mol Psychiatry. 2019 Mar 13. doi: 10.1038/s41380-019-0398-0. [Epub ahead of print] Review.

Learn more Learn more
Pregnancy history and cognitive aging among older women: the Rancho Bernardo Study. PMID: 30889095

Ilango SD, McEvoy LK, Laughlin GA, Bergstrom J, Barrett-Connor E, Kritz-Silverstein D.Menopause. 2019 Mar 18. doi: 10.1097/GME.0000000000001318. [Epub ahead of print]

Learn more Learn more
Efficacy of Fish Oil and/or Probiotic Intervention on the Incidence of Gestational Diabetes Mellitus in an At-Risk Group of Overweight and Obese Women: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial. PMID: 30967436

Pellonperä O, Mokkala K, Houttu N, Vahlberg T, Koivuniemi E, Tertti K, Rönnemaa T, Laitinen K.Diabetes Care. 2019 Apr 9. pii: dc182591. doi: 10.2337/dc18-2591. [Epub ahead of print]

Learn more Learn more
Acute Management of Ischemic Stroke During Pregnancy. PMID: 30969218

Pacheco LD, Hankins GDV, Saad AF, Saade GR.Obstet Gynecol. 2019 Apr 5. doi: 10.1097/AOG.0000000000003220. [Epub ahead of print]

Learn more Learn more
Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation. PMID: 31116405

Poirot C, Fortin A, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Brice P, Morice P, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Gouy S, Chalas C, Egels S, Dhédin N, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N; CAROLéLISA Cooperative Group.Hum Reprod. 2019 May 22. pii: dez047. doi: 10.1093/humrep/dez047. [Epub ahead of print]

Learn more Learn more
Breastfeeding and pelvic floor disorders one to two decades after vaginal delivery. PMID: 31108062

Lovejoy DA, Roem JL, Blomquist JL, Pandya PR, Handa VL.Am J Obstet Gynecol. 2019 May 17. pii: S0002-9378(19)30668-4. doi: 10.1016/j.ajog.2019.05.010. [Epub ahead of print]

Learn more Learn more
Effect of maternal lifestyle intervention on metabolic health and adiposity of offspring: Findings from the Finnish Gestational Diabetes Prevention Study (RADIEL). PMID: 31175958

Grotenfelt NE, Wasenius N, Eriksson JG, Huvinen E, Stach-Lempinen B, Koivusalo SB, Rönö K.Diabetes Metab. 2019 Jun 5. pii: S1262-3636(19)30090-4. doi: 10.1016/j.diabet.2019.05.007. [Epub ahead of print]

Learn more Learn more
Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. PMID: 31176553

Aro K, Nieminen P, Louvanto K, Jakobsson M, Virtanen S, Lehtinen M, Dillner J, Kalliala I.Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31268-5. doi: 10.1016/j.ygyno.2019.05.024. [Epub ahead of print]

Learn more Learn more
Probiotics in pregnancy: protocol of a double-blind randomized controlled pilot trial for pregnant women with depression and anxiety (PIP pilot trial). PMID: 31315657

Browne PD, Bolte A, Claassen E, de Weerth C.Trials. 2019 Jul 17;20(1):440. doi: 10.1186/s13063-019-3389-1.

Learn more Learn more
Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: a systematic review and meta-analysis. PMID: 31318420

Horton J, Sterrenburg M, Lane S, Maheshwari A, Li TC, Cheong Y.Hum Reprod Update. 2019 Jul 18. pii: dmz012. doi: 10.1093/humupd/dmz012. [Epub ahead of print]

Learn more Learn more
Association between fetal sex, birthweight percentile and adverse pregnancy outcome. PMID: 31424085

Voskamp BJ, Peelen MJCS, Ravelli ACJ, van der Lee R, Mol BWJ, Pajkrt E, Ganzevoort W, Kazemier BM.Acta Obstet Gynecol Scand. 2019 Aug 19. doi: 10.1111/aogs.13709. [Epub ahead of print]

Learn more Learn more
Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. PMID: 31429897

Consortium on Thyroid and Pregnancy—Study Group on Preterm Birth, Korevaar TIM, Derakhshan A, Taylor PN,et al.JAMA. 2019 Aug 20;322(7):632-641. doi: 10.1001/jama.2019.10931.

Learn more Learn more
Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy With Uterosacral Ligament Suspension on Treatment Failure in Women With Uterovaginal Prolapse: A Randomized Clinical Trial. PMID: 31529008

Nager CW, Visco AG, Richter HE, Rardin CR, Rogers RG, Harvie HS, Zyczynski HM, Paraiso MFR, Mazloomdoost D, Grey S, Sridhar A, Wallace D; NICHD Pelvic Floor Disorders NetworkJAMA. 2019 Sep 17;322(11):1054-1065. doi: 10.1001/jama.2019.12812.

Learn more Learn more
Global Consensus Position Statement on the use of Testosterone Therapy for Women. PMID: 31484631

Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME.Maturitas. 2019 Jul 17. pii: S0378-5122(19)30628-0. doi: 10.1016/j.maturitas.2019.07.001. [Epub ahead of print] No abstract available.

Learn more Learn more
Progression of deep infiltrating rectosigmoid endometriotic nodules. PMID: 31687764

Netter A, d’Avout-Fourdinier P, Agostini A, Chanavaz-Lacheray I, Lampika M, Farella M, Hennetier C, Roman H.Hum Reprod. 2019 Nov 4. pii: dez188. doi: 10.1093/humrep/dez188. [Epub ahead of print]

Learn more Learn more
30-Day Unanticipated Healthcare Encounters After Prolapse Surgery: Impact of Same Day Discharge. PMID: 31733206

Romanova AL, Carter-Brooks C, Ruppert KM, Zyczynski HM.Am J Obstet Gynecol. 2019 Nov 13. pii: S0002-9378(19)32621-3. doi: 10.1016/j.ajog.2019.11.1249. [Epub ahead of print]

Learn more Learn more
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. PMID: 31845767

Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH.Cochrane Database Syst Rev. 2019 Dec 17;12:CD013505. doi: 10.1002/14651858.CD013505. Review.

Learn more Learn more
Coverage of immediate postpartum long acting reversible contraception has improved birth intervals for at risk populations. PMID: 31846612

Liberty A, Yee K, Darney BG, Lopez-Defede A, Rodriguez MI.Am J Obstet Gynecol. 2019 Dec 14. pii: S0002-9378(19)32703-6. doi: 10.1016/j.ajog.2019.11.1282. [Epub ahead of print]

Learn more Learn more
A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. PMID: 31916574

Amiri M, Nahidi F, Bidhendi-Yarandi R, Khalili D, Tohidi M, Ramezani Tehrani F.Hum Reprod. 2020 Jan 9. pii: dez255. doi: 10.1093/humrep/dez255. [Epub ahead of print]

Learn more Learn more
An economic analysis of preimplantation genetic testing for aneuploidy (PGT-A) by polar body biopsy in advanced maternal age. PMID: 31930663

Neumann K, Sermon K, Bossuyt P, Goossens V, Geraedts J, Traeger-Synodinos J, Parriego M, Schmutzler A, van der Ven K, Rudolph-Rothfeld W, Vonthein R, Griesinger G.BJOG. 2020 Jan 12. doi: 10.1111/1471-0528.16089. [Epub ahead of print]

Learn more Learn more
Examining indicators of early menopause following opportunistic salpingectomy: A cohort study from British Columbia, Canada. PMID: 32067967

Hanley GE, Kwon JS, McAlpine JN, Huntsman DG, Finlayson SJ, Miller D.Am J Obstet Gynecol. 2020 Feb 14. pii: S0002-9378(20)30143-5. doi: 10.1016/j.ajog.2020.02.005. [Epub ahead of print]

Learn more Learn more
Is there enough evidence to justify the use of laser and other thermal therapies in female lower urinary tract dysfunction? Report from the ICI-RS 2019. PMID: 32040871

Robinson D, Flint R, Veit-Rubin N, Araklitis G, Cardozo L.Neurourol Urodyn. 2020 Feb 10. doi: 10.1002/nau.24298. [Epub ahead of print] Review.

Learn more Learn more
Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. PMID: 32187665

Russo M, Newell JM, Budurlean L, Houser KR, Sheldon K, Kesterson J, Phaeton R, Hossler C, Rosenberg J, DeGraff D, Shuman L, Broach JR, Warrick JI.Cancer. 2020 Mar 18. doi: 10.1002/cncr.32822. [Epub ahead of print]

Learn more Learn more
Maternal risk factors and adverse birth outcomes associated with HELLP syndrome: a population-based study. PMID: 32189413

Lisonkova S, Razaz N, Sabr Y, Muraca GM, Boutin A, Mayer C, Joseph KS, Kramer MS.BJOG. 2020 Mar 19. doi: 10.1111/1471-0528.16225. [Epub ahead of print]

Learn more Learn more
Challenges in conducting clinical research studies in pregnant women. PMID: 32306165

McKiever M, Frey H, Costantine MM.J Pharmacokinet Pharmacodyn. 2020 Apr 18. doi: 10.1007/s10928-020-09687-z. Online ahead of print.

Learn more Learn more
Role of sex steroid hormones in pelvic organ prolapse. PMID: 32301895

Reddy RA, Cortessis V, Dancz C, Klutke J, Stanczyk FZ.Menopause. 2020 Apr 13. doi: 10.1097/GME.0000000000001546. Online ahead of print.

Learn more Learn more
Molecular and cellular mechanisms linking air pollution and bone damage. PMID: 32305664

Prada D, López G, Solleiro-Villavicencio H, Garcia-Cuellar C, Baccarelli AA.Environ Res. 2020 Apr 6;185:109465. doi: 10.1016/j.envres.2020.109465. Online ahead of print.

Learn more Learn more
Fragility fractures in Europe: burden, management and opportunities. PMID: 32306163

Borgström F, Karlsson L, Ortsäter G, Norton N, Halbout P, Cooper C, Lorentzon M, McCloskey EV, Harvey NC, Javaid MK, Kanis JA; International Osteoporosis Foundation.Arch Osteoporos. 2020 Apr 19;15(1):59. doi: 10.1007/s11657-020-0706-y.

Learn more Learn more
Association of Pharmacist Prescription With Dispensed Duration of Hormonal Contraception. PMID: 32432710

Rodriguez MI, Edelman AB, Skye M, Anderson L, Darney BG.JAMA Netw Open. 2020 May 1;3(5):e205252. doi: 10.1001/jamanetworkopen.2020.5252.

Learn more Learn more
Clinical Findings and Disease Severity in Hospitalized Pregnant Women With Coronavirus Disease 2019 (COVID-19). PMID: 32433453

Savasi VM, Parisi F, Patanè L, Ferrazzi E, Frigerio L, Pellegrino A, Spinillo A, Tateo S, Ottoboni M, Veronese P, Petraglia F, Vergani P, Facchinetti F, Spazzini D, Cetin I.Obstet Gynecol. 2020 May 19. doi: 10.1097/AOG.0000000000003979. Online ahead of print.

Learn more Learn more
Development of children born from freeze-only versus fresh embryo transfer: follow-up of a randomized controlled trial. PMID: 32560970

Vuong LN, Ly TT, Nguyen NA, Nguyen LMT, Le XTH, Le TK, Le KTQ, Le TV, Nguyen MHN, Dang VQ, Norman RJ, Mol BW, Ho TM.Fertil Steril. 2020 Jun 16:S0015-0282(20)30401-5. doi: 10.1016/j.fertnstert.2020.04.041. Online ahead of print.

Learn more Learn more
Re-Engineering Academic Departments of Obstetrics and Gynecology to Operate in a Pandemic World and Beyond – A Joint AGOS/CUCOG Statement. PMID: 32561227

Alvarez RD, Goff BA, Chelmow D, Griffin TR, Norwitz ER, Lancey JO.Am J Obstet Gynecol. 2020 Jun 16:S0002-9378(20)30642-6. doi: 10.1016/j.ajog.2020.06.024. Online ahead of print.

Learn more Learn more
Effect of menstrual cycle on resting metabolism: A systematic review and meta-analysis. PMID: 32658929

Benton MJ, Hutchins AM, Dawes JJ.PLoS One. 2020 Jul 13;15(7):e0236025. doi: 10.1371/journal.pone.0236025. eCollection 2020.

Learn more Learn more
Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. PMID: 32683695

Ahmad G, Thompson M, Kim K, Agarwal P, Mackie FL, Dias S, Metwally M, Watson A.Cochrane Database Syst Rev. 2020 Jul 17;7:CD001298. doi: 10.1002/14651858.CD001298.pub5.

Learn more Learn more
Cancer patients with fractures are rarely assessed or treated for osteoporosis: a population-based study. PMID: 32808139

Leslie WD, Edwards B, Al-Azazi S, Yan L, Lix LM, Czaykowski P, Singh H.Osteoporos Int. 2020 Aug 17. doi: 10.1007/s00198-020-05596-6. Online ahead of print.

Learn more Learn more
Bone mineral density and osteoporosis in relation to all-cause and cause-specific mortality in NHANES: a population-based cohort study. PMID: 32814125

Cai S, Fan J, Zhu L, Ye J, Rao X, Fan C, Zhong Y, Li Y.Bone. 2020 Aug 16:115597. doi: 10.1016/j.bone.2020.115597. Online ahead of print.

Learn more Learn more
To share or not to share data: how valid are trials evaluating first-line ovulation induction for polycystic ovary syndrome? PMID: 32935841

Bordewijk EM, Wang R, van Wely M, Costello MF, Norman RJ, Teede H, Gurrin LC, Mol BW, Li W.Hum Reprod Update. 2020 Sep 16:dmaa031. doi: 10.1093/humupd/dmaa031. Online ahead of print.

Learn more Learn more
Maternal obesity influences placental nutrient transport, inflammatory status and morphology in human term placenta. PMID: 32936881

Nogues P, Dos Santos E, Couturier-Tarrade A, Berveiller P, Arnould L, Lamy E, Grassin-Delyle S, Vialard F, Dieudonne MN.J Clin Endocrinol Metab. 2020 Sep 16:dgaa660. doi: 10.1210/clinem/dgaa660. Online ahead of print.

Learn more Learn more
Pregnancy and delivery outcomes in women with rectovaginal endometriosis treated either conservatively or operatively. PMID: 33039131

Tuominen A, Saavalainen L, Tiitinen A, Heikinheimo O, Härkki P.Fertil Steril. 2020 Oct 8:S0015-0282(20)30713-5. doi: 10.1016/j.fertnstert.2020.07.051. Online ahead of print.

Learn more Learn more
Determinants of referral of women with urinary incontinence to specialist services: a national cohort study using primary care data from the UK. PMID: 33066730

Gurol-Urganci I, Geary RS, Mamza JB, Iwagami M, El-Hamamsy D, Duckett J, Wilson A, Tincello D, van der Meulen J.BMC Fam Pract. 2020 Oct 16;21(1):211. doi: 10.1186/s12875-020-01282-y.

Learn more Learn more
Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. PMID: 33057738

McCloskey EV, Harvey NC, Johansson H, Lorentzon M, Vandenput L, Liu E, Kanis JA.Osteoporos Int. 2020 Oct 14. doi: 10.1007/s00198-020-05542-6. Online ahead of print.

Learn more Learn more
Decline of ovarian function in patients with rheumatoid arthritis: serum anti-Müllerian hormone levels in a longitudinal cohort. PMID: 33040022

Brouwer J, Dolhain RJEM, Hazes JMW, Erler NS, Visser JA, Laven JSE.RMD Open. 2020 Oct;6(3):e001307. doi: 10.1136/rmdopen-2020-001307.

Learn more Learn more
The impact of frailty in older women undergoing pelvic floor reconstructive surgery. PMID: 33177412

Shaw JS, Erekson E, Richter HE.Menopause. 2020 Nov 9. doi: 10.1097/GME.0000000000001681. Online ahead of print.

Learn more Learn more
Reproductive hormones and anthropometry: a follow-up of PCOS and controls from perimenopause to above 80 years of age. PMID: 33205205

Forslund M, Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E.J Clin Endocrinol Metab. 2020 Nov 17:dgaa840. doi: 10.1210/clinem/dgaa840. Online ahead of print.

Learn more Learn more
Double-blind RCT of fish oil supplementation in pregnancy and lactation to improve the metabolic health in children of mothers with overweight or obesity during pregnancy: study protocol. PMID: 33323442

Satokar VV, Cutfield WS, Derraik JGB, Harwood M, Okasene-Gafa K, Beck K, Cameron-Smith D, O’Sullivan JM, Sundborn G, Pundir S, Mason RP, Albert BB.BMJ Open. 2020 Dec 15;10(12):e041015. doi: 10.1136/bmjopen-2020-041015.

Learn more Learn more
Multi-professional simulation-based team training in obstetric emergencies for improving patient outcomes and trainees’ performance. PMID: 33325570

Fransen AF, van de Ven J, Banga FR, Mol BWJ, Oei SG.Cochrane Database Syst Rev. 2020 Dec 16;12:CD011545. doi: 10.1002/14651858.CD011545.pub2.

Learn more Learn more
Black-White disparities in maternal in-hospital mortality according to teaching and Black-serving hospital status. PMID: 33453183

Burris HH, Passarella M, Handley SC, Srinivas SK, Lorch SA.Am J Obstet Gynecol. 2021 Jan 13:S0002-9378(21)00027-2. doi: 10.1016/j.ajog.2021.01.004. Online ahead of print.

Learn more Learn more
Vitamin D and bone health status in beta thalassemia patients-systematic review. PMID: 33423084

Manolopoulos PP, Lavranos G, Mamais I, Angouridis A, Giannakou K, Johnson EO.Osteoporos Int. 2021 Jan 9. doi: 10.1007/s00198-021-05821-w. Online ahead of print.

Learn more Learn more
Black-White disparities in maternal in-hospital mortality according to teaching and Black-serving hospital status. PMID: 33453183

Burris HH, Passarella M, Handley SC, Srinivas SK, Lorch SA.Am J Obstet Gynecol. 2021 Jan 13:S0002-9378(21)00027-2. doi: 10.1016/j.ajog.2021.01.004. Online ahead of print.

Learn more Learn more
The development of the human uterus: morphogenesis to menarche. PMID: 33395479

Habiba M, Heyn R, Bianchi P, Brosens I, Benagiano G.Hum Reprod Update. 2021 Jan 4;27(1):1-26. doi: 10.1093/humupd/dmaa036.

Learn more Learn more
Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822. PMID: 33595252

Obstet Gynecol. 2021 Mar 1;137(3):e63-e74.doi: 10.1097/AOG.0000000000004291.

Learn more Learn more
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. PMID: 33596357

Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA.N Engl J Med. 2021 Feb 18;384(7):630-642.doi: 10.1056/NEJMoa2008283.

Learn more Learn more
Bisphosphonates in inflammatory rheumatic diseases. PMID: 33592328

Peris P, Monegal A, Guañabens N.Bone. 2021 Feb 13:115887.doi: 10.1016/j.bone.2021.115887. Online ahead of print.

Learn more Learn more
Role of bone-forming agents in the management of osteoporosis. PMID: 33594648

McClung MR.Aging Clin Exp Res. 2021 Feb 16.doi: 10.1007/s40520-020-01708-8. Online ahead of print.

Learn more Learn more
Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. PMID: 33743481

Seppälä TT, Dominguez-Valentin M, Crosbie EJ, et al.Eur J Cancer. 2021 Mar 17;148:124-133. doi: 10.1016/j.ejca.2021.02.022. Online ahead of print.

Learn more Learn more
Prenatal exposure to maternal stressful life events and earlier age at menarche: the Raine Study. PMID: 33744952

Bräuner EV, Koch T, Juul A, Doherty DA, Hart R, Hickey M.Hum Reprod. 2021 Mar 21:deab039. doi: 10.1093/humrep/deab039. Online ahead of print.

Learn more Learn more
Telemedicine for contraceptive counseling: patient experiences during the early phase of the Covid-19 pandemic in New York City. PMID: 33861981

Stifani BM, Smith A, Avila K, Boos EW, Ng J, Levi EE, Benfield NC.Contraception. 2021 Apr 13:S0010-7824(21)00111-6. doi: 10.1016/j.contraception.2021.04.006. Online ahead of print.

Learn more Learn more
Markers of vitamin D metabolism and premenstrual symptoms in healthy women with regular cycles. PMID: 33864070

Alkhalaf Z, Kim K, Kuhr DL, Radoc JG, Purdue-Smithe A, Pollack AZ, Yisahak SF, Silver RM, Thoma M, Kissell K, Perkins NJ, Sjaarda LA, Mumford SL.Hum Reprod. 2021 Apr 16:deab089. doi: 10.1093/humrep/deab089. Online ahead of print.

Learn more Learn more
Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome. PMID: 33860677

Hsu CY, Su YJ, Chen JF, Sun CC, Cheng TT, Tsai TH, Lin SH, Chang CC, Chen TH.J Am Heart Assoc. 2021 Apr 16:e018290. doi: 10.1161/JAHA.120.018290. Online ahead of print.

Learn more Learn more
Effect of selenium supplementation on musculoskeletal health in older women: a randomised, double-blind, placebo-controlled trial. PMID: 33842907

Walsh JS, Jacques RM, Schomburg L, Hill TR, Mathers JC, Williams GR, Eastell R.Lancet Healthy Longev. 2021 Apr;2(4):e212-e221. doi: 10.1016/S2666-7568(21)00051-9.

Learn more Learn more
Impact of exercise on pain perception in women with endometriosis: a systematic review. PMID: 33999412

Hansen S, Sverrisdóttir UÁ, Rudnicki M.Acta Obstet Gynecol Scand. 2021 May 17. doi: 10.1111/aogs.14169. Online ahead of print.

Learn more Learn more
Acceptability of Text Messaging and Disparities in Mobile Health Access in Women’s Health Care: A Survey Study. PMID: 33999723

Dahl M, Morocco E, Rodriguez L, Dancz CE.Telemed J E Health. 2021 May 17. doi: 10.1089/tmj.2020.0516. Online ahead of print.

Learn more Learn more
Incidence, prevalence and trends in endometriosis diagnosis: A United States population-based study from 2006-2015. PMID: 34147493

Christ JP, Yu O, Schulze-Rath R, Grafton J, Hansen K, Reed SD.Am J Obstet Gynecol. 2021 Jun 17:S0002-9378(21)00700-6. doi: 10.1016/j.ajog.2021.06.067. Online ahead of print.

Learn more Learn more
Evaluation of clinical practice guidelines (CPG) on the management of female chronic pelvic pain (CPP) using the AGREE II instrument. PMID: 34148114

Ghai V, Subramanian V, Jan H, Loganathan J, Doumouchtsis SK; CHORUS: An International Collaboration for Harmonising Outcomes, Research and Standards in Urogynaecology and Women’s Health (i-chorus.org).Int Urogynecol J. 2021 Jun 19. doi: 10.1007/s00192-021-04848-1. Online ahead of print.

Learn more Learn more
Satisfaction with maternity care among recent migrants: an interview questionnaire-based study. PMID: 34272220

Bains S, Sundby J, Lindskog BV, Vangen S, Diep LM, Owe KM, Sorbye IK.BMJ Open. 2021 Jul 16;11(7):e048077. doi: 10.1136/bmjopen-2020-048077.

Learn more Learn more
Migration, gestational diabetes and adverse pregnancy outcomes: a nationwide study of singleton deliveries in Denmark. PMID: 34272865

Kragelund Nielsen K, Andersen GS, Damm P, Andersen AN.J Clin Endocrinol Metab. 2021 Jul 17:dgab528. doi: 10.1210/clinem/dgab528. Online ahead of print.

Learn more Learn more
Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. PMID: 34387117

Cruickshank T, MacDonald TM, Walker SP, Keenan E, Dane K, Middleton A, Kyritsis V, Myers J, Cluver C, Hastie R, Bergman L, Garcha D, Cannon P, Murray E, Nguyen TV, Hiscock R, Pritchard N, Hannan NJ, Tong S, Kaitu’u-Lino TJ.J Am Heart Assoc. 2021 Aug 13:e020302. doi: 10.1161/JAHA.120.020302. Online ahead of print.

Learn more Learn more
COVID-19 Vaccination During Pregnancy: Coverage and Safety. PMID: 34389291

Blakeway H, Prasad S, Kalafat E, Heath PT, Ladhani SN, Le Doare K, Magee LA, O’brien P, Rezvani A, Dadelszen PV, Khalil A.Am J Obstet Gynecol. 2021 Aug 10:S0002-9378(21)00873-5. doi: 10.1016/j.ajog.2021.08.007. Online ahead of print.

Learn more Learn more
Knowledge and Needs of Resident Physicians Regarding Osteoporosis: A Nationwide Survey of Residents. PMID: 34368610

Crandall CJ, Chen LY, Rodriguez TD, Elashoff D, Faubion SS, Kling JM, Shifren J, Skinner L, Bauer DC.JBMR Plus. 2021 Jul 1;5(8):e10524. doi: 10.1002/jbm4.10524. eCollection 2021 Aug.

Learn more Learn more
Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. PMID: 34379148

Schemitsch E, Adachi JD, Brown JP, Tarride JE, Burke N, Oliveira T, Slatkovska L.Osteoporos Int. 2021 Aug 11:1-10. doi: 10.1007/s00198-021-06080-5. Online ahead of print.

Learn more Learn more
Knowledge and Needs of Resident Physicians Regarding Osteoporosis: A Nationwide Survey of Residents. PMID: 34368610

Crandall CJ, Chen LY, Rodriguez TD, Elashoff D, Faubion SS, Kling JM, Shifren J, Skinner L, Bauer DC.JBMR Plus. 2021 Jul 1;5(8):e10524. doi: 10.1002/jbm4.10524. eCollection 2021 Aug.

Learn more Learn more
Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. PMID: 34379148

Schemitsch E, Adachi JD, Brown JP, Tarride JE, Burke N, Oliveira T, Slatkovska L.Osteoporos Int. 2021 Aug 11:1-10. doi: 10.1007/s00198-021-06080-5. Online ahead of print.

Learn more Learn more
Knowledge and Needs of Resident Physicians Regarding Osteoporosis: A Nationwide Survey of Residents. PMID: 34368610

Crandall CJ, Chen LY, Rodriguez TD, Elashoff D, Faubion SS, Kling JM, Shifren J, Skinner L, Bauer DC.JBMR Plus. 2021 Jul 1;5(8):e10524. doi: 10.1002/jbm4.10524. eCollection 2021 Aug.

Learn more Learn more
Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. PMID: 34379148

Schemitsch E, Adachi JD, Brown JP, Tarride JE, Burke N, Oliveira T, Slatkovska L.Osteoporos Int. 2021 Aug 11:1-10. doi: 10.1007/s00198-021-06080-5. Online ahead of print.

Learn more Learn more
Risk of reoperation 10 years after surgical treatment for stress urinary incontinence: a national population-based cohort study. PMID: 34509439

Muller P, Gurol-Urganci I, Meulen JV, Thakar R, Jha S.Am J Obstet Gynecol. 2021 Sep 9:S0002-9378(21)00996-0. doi: 10.1016/j.ajog.2021.08.059. Online ahead of print.

Learn more Learn more
Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study. PMID: 34506535

osteira R, Lee KA, Murray B, Christiansen C, Castillo-Fernandez J, Ni Lochlainn M, Capdevila Pujol J, Macfarlane H, Kenny LC, Buchan I, Wolf J, Rymer J, Ourselin S, Steves CJ, Spector TD, Newson LR, Bell JT.PLoS One. 2021 Sep 10;16(9):e0257051. doi: 10.1371/journal.pone.0257051. eCollection 2021.

Learn more Learn more
Pregnancy and risk of COVID-19: a Norwegian registry-linkage study. PMID: 34657368

Magnus MC, Oakley L, Gjessing HK, Stephansson O, Engjom HM, Macsali F, Juliusson PB, Andersen AN, Håberg SE.BJOG. 2021 17 October. doi: 10.1111/1471-0528.16969. Online ahead of print.

Learn more Learn more
The Association of Physical Activity and Urinary Incontinence in US Women: Results from a Multi-Year National Survey. PMID: 34644590

Kim MM, Ladi-Seyedian SS, Ginsberg DA, Kreydin EI.Urology. 2021 Oct 10:S0090-4295(21)00915-8. doi: 10.1016/j.urology.2021.09.022. Online ahead of print.

Learn more Learn more
The outcomes of shoulder arthroplasty in those over 70 years with glenohumeral arthritis: A New Zealand Joint Registry Study. PMID: 34656778

Mowbray J, Van Niekerk M, Frampton C, Hirner M.J Shoulder Elbow Surg. 2021 Oct 14:S1058-2746(21)00713-8. doi: 10.1016/j.jse.2021.09.006. Online ahead of print.

Learn more Learn more
Risk of subtrochanteric and femoral shaft fractures due to bisphosphonate therapy in asthma: a population-based nested case-control study. PMID: 34635953

Chalitsios CV, Shaw DE, McKeever TM.Osteoporos Int. 2021 11 October. doi: 10.1007/s00198-021-06197-7. Online ahead of print.

Learn more Learn more
Fecal incontinence in non-pregnant nulliparous women aged 25-64 years – a randomly selected national cohort prevalence study. PMID: 34774822

Al-Mukhtar Othman J, Åkervall S, Nilsson IEK, Molin M, Milsom I, Gyhagen M.Am J Obstet Gynecol. 2021 Nov 11:S0002-9378(21)01229-1. doi: 10.1016/j.ajog.2021.11.032. Online ahead of print.

Learn more Learn more
Management of Critically Ill Pregnant Patients with COVID-19 Infection in a Rural State. PMID: 34775583

Pagan ME, Ramseyer AM, Whitcombe DD, Doiron TE, Magann EF, Sandlin AT, Hughes DS.Am J Perinatol. 2021 Nov 14. doi: 10.1055/s-0041-1739292. Online ahead of print.

Learn more Learn more
Obstetric Complications in Women With Congenital Uterine Anomalies According to the 2013 European Society of Human Reproduction and Embryology and the European Society for Gynaecological Endoscopy Classification: A Systematic Review and Meta-analysis. PMID: 34856567

Panagiotopoulos M, Tseke P, Michala L.Obstet Gynecol. 2021 Dec 2. doi: 10.1097/AOG.0000000000004627. Online ahead of print.

Learn more Learn more
Sleep-disordered breathing in high-risk pregnancies is associated with elevated arterial stiffness and increased risk for preeclampsia. PMID: 34863697

Phan K, Pamidi S, Gomez YH, Gorgui J, El-Messidi A, Gagnon R, Kimoff RJ, Daskalopoulou SS.Am J Obstet Gynecol. 2021 Dec 1:S0002-9378(21)02626-0. doi: 10.1016/j.ajog.2021.11.1366. Online ahead of print.

Learn more Learn more
Associations of osteoporosis and sarcopenia with frailty and multimorbidity among participants of the Hertfordshire Cohort Study. PMID: 34873876

Laskou F, Fuggle NR, Patel HP, Jameson K, Cooper C, Dennison E.J Cachexia Sarcopenia Muscle. 2021 Dec 6. doi: 10.1002/jcsm.12870. Online ahead of print.

Learn more Learn more
Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. PMID: 34896359

Ebetino FH, Sun S, Cherian P, Roshandel S, Neighbors JD, Hu E, Dunford JE, Sedghizadeh PP, McKenna CE, Srinivasan V, Boeckman RK, Russell RGG.Bone. 2021 Dec 8:116289. doi: 10.1016/j.bone.2021.116289. Online ahead of print.

Learn more Learn more
The effect of maternal SARS-CoV-2 infection timing on birth outcomes: a retrospective multicentre cohort study. PMID: 35034863

Piekos SN, Roper RT, Hwang YM, Sorensen T, Price ND, Hood L, Hadlock JJ.Lancet Digit Health. 2022 Jan 13:S2589-7500(21)00250-8. doi: 10.1016/S2589-7500(21)00250-8. Online ahead of print.

Learn more Learn more
Survey of lower urinary tract symptoms in United States women using the new lower urinary tract dysfunction research Network-Symptom Index 29 (LURN-SI-29) and a national research registry. PMID: 35032354

Smith AL, Chen J, Wyman JF, Newman DK, Berry A, Schmitz K, Stapleton AE, Klusaritz H, Lin G, Stambakio H, Sutcliffe S.Neurourol Urodyn. 2022 Jan 15. doi: 10.1002/nau.24870. Online ahead of print.

Learn more Learn more
The risk of endometrial malignancy and other endometrial pathology in women with abnormal uterine bleeding: an ultrasound-based model development study by the IETA group. PMID: 35152217

Wynants L, Verbakel JYJ, Valentin L, De Cock B, Pascual MA, Leone FPG, Sladkevicius P, Heremans R, Alcázar JL, Votino A, Fruscio R, Epstein E, Bourne T, Van Calster B, Timmerman D, Van den Bosch T.Gynecol Obstet Invest. 2022 Feb 11. doi: 10.1159/000522524. Online ahead of print.

Learn more Learn more
Disparities in Reproductive Aging and Midlife Health between Black and White women: The Study of Women’s Health Across the Nation (SWAN). PMID: 35130984

Harlow SD, Burnett-Bowie SM, Greendale GA, Avis NE, Reeves AN, Richards TR, Lewis TT.Womens Midlife Health. 2022 Feb 8;8(1):3. doi: 10.1186/s40695-022-00073-y.

Learn more Learn more
Women with female infertility seeking medically assisted reproduction are not at increased risk of developing multiple sclerosis. PMID: 35265993

Kopp TI, Pinborg A, Glazer CH, Magyari M.Hum Reprod. 2022 Mar 10:deac041. doi: 10.1093/humrep/deac041. Online ahead of print.

Learn more Learn more
Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. PMID: 35264408

Harding C, Mossop H, Homer T, Chadwick T, King W, Carnell S, Lecouturier J, Abouhajar A, Vale L, Watson G, Forbes R, Currer S, Pickard R, Eardley I, Pearce I, Thiruchelvam N, Guerrero K, Walton K, Hussain Z, Lazarowicz H, Ali A.BMJ. 2022 Mar 9;376:e068229. doi: 10.1136/bmj-2021-0068229.

Learn more Learn more
Health Care in Pregnancy During the COVID-19 Pandemic and Pregnancy Outcomes in Six Low-and-Middle-Income Countries: Evidence from a Prospective, Observational Registry of the Global Network for Women’s and Children’s Health. PMID: 35377514

Naqvi S, Naqvi F, Saleem S, Thorsten VR, Figueroa L, et al.BJOG. 2022 Apr 4. doi: 10.1111/1471-0528.17175. Online ahead of print.

Learn more Learn more
Society for Maternal-Fetal Medicine (SMFM) Consult Series #62: Best practices in equitable care delivery: Addressing systemic racism and other social determinants of health as causes of obstetric disparities PMID: 35378098

Society for Maternal-Fetal Medicine (SMFM) Publications Committee, Greenberg MB, Gandhi M, Davidson C, Carter EB.Am J Obstet Gynecol. 2022 Apr 1:S0002-9378(22)00266-6. doi: 10.1016/j.ajog.2022.04.001. Online ahead of print.

Learn more Learn more
The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state-of-the-art review. PMID: 35484706

Mortensen OE, Christensen SE, Løkkegaard E.Acta Obstet Gynecol Scand. 2022 Apr 28. doi: 10.1111/aogs.14353. Online ahead of print.

Learn more Learn more
Salpingo-Oophorectomy or Surveillance for Ovarian Endometrioma in Asymptomatic Premenopausal Women: a Cost-Effectiveness Analysis. PMID: 35490792

Orlando MS, Cadish LA, Shepherd JP, Falcone T, Chang OH, Kho RM.Am J Obstet Gynecol. 2022 Apr 28:S0002-9378(22)00324-6. doi: 10.1016/j.ajog.2022.04.043. Online ahead of print.

Learn more Learn more
Multilevel determinants of racial/ethnic disparities in severe maternal morbidity and mortality in the context of the COVID-19 pandemic in the USA: protocol for a concurrent triangulation, mixed-methods study. PMID: 35688597

Liu J, Hung P, Liang C, Zhang J, Qiao S, Campbell BA, Olatosi B, Torres ME, Hikmet N, Li X.BMJ Open. 2022 Jun 10;12(6):e062294. doi: 10.1136/bmjopen-2022-062294.

Learn more Learn more
Prolapse and mesh reoperations following sacrocolpopexy: comparing supracervical hysterectomy, total hysterectomy, and no hysterectomy. PMID: 35689689

Kikuchi JY, Yanek LR, Handa VL, Chen CCG, Jacobs S, Blomquist J, Patterson D.Int Urogynecol J. 2022 Jun 11. doi: 10.1007/s00192-022-05263-w. Online ahead of print.

Learn more Learn more
Reproductive medicine in the face of climate change: a call for prevention through leadership. PMID: 35787921

Martin L, Zhang Y, Mustieles V, Souter I, Petrozza J, Messerlian C.Fertil Steril. 2022 Jul 1:S0015-0282(22)00388-0. doi: 10.1016/j.fertnstert.2022.06.010. Online ahead of print.

Learn more Learn more
Association of life-course reproductive duration with mortality: a population-based twin cohort study. PMID: 35779587

Li X, Wang S, Dunk M, Yang W, Qi X, Sun Z, Xu W.Am J Obstet Gynecol. 2022 Jun 29:S0002-9378(22)00529-4. doi: 10.1016/j.ajog.2022.06.053. Online ahead of print.

Learn more Learn more
Long-term Symptom Trajectories in Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study. PMID: 35961564

Bradley CS, Gallop R, Sutcliffe S, Kreder KJ, Lai HH, Clemens JQ, Naliboff BD; Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.Urology. 2022 Aug 9:S0090-4295(22)00654-9. doi: 10.1016/j.urology.2022.07.045. Online ahead of print.

Learn more Learn more
Selective serotonin reuptake inhibitors and preeclampsia: A quality assessment and meta-analysis. PMID: 35963154

Gumusoglu SB, Schickling BM, Vignato JA, Santillan DA, Santillan MK.Pregnancy Hypertens. 2022 Aug 6;30:36-43. doi: 10.1016/j.preghy.2022.08.001. Online ahead of print.

Learn more Learn more
Effectiveness of proprioceptive neuromuscular facilitation therapy and strength training among post-menopausal women with thumb carpometacarpal osteoarthritis. A randomized trial. PMID: 35948454

Campos-Villegas C, Pérez-Alenda S, Carrasco JJ, Igual-Camacho C, Tomás-Miguel JM, Cortés-Amador S.J Hand Ther. 2022 Aug 7:S0894-1130(22)00080-1. doi: 10.1016/j.jht.2022.07.005. Online ahead of print.

Learn more Learn more
Early-onset osteoporosis: Rare monogenic forms elucidate the complexity of disease pathogenesis beyond type I collagen. PMID: 35949115

Costantini A, Mäkitie RE, Hartmann MA, Fratzl-Zelman N, Zillikens MC, Kornak U, Søe K, Mäkitie O.J Bone Miner Res. 2022 Aug 10. doi: 10.1002/jbmr.4668. Online ahead of print.

Learn more Learn more
Comparison of #Enzian classification and revised American Society for Reproductive Medicine stages for the description of disease extent in women with deep endometriosis. PMID: 36066464

Montanari E, Bokor A, Szabó G, Kondo W, Trippia CH, Malzoni M, Di Giovanni A, Tinneberg HR, Oberstein A, Rocha RM, Leonardi M, Condous G, Alsalem H, Keckstein J, Hudelist G.Hum Reprod. 2022 Sep 6:deac187. doi: 10.1093/humrep/deac187. Online ahead of print.

Learn more Learn more
Contraceptive efficacy and safety of 52mg LNG-IUS for up to 8 years: findings from the Mirena Extension Trial. PMID: 36096186

Jensen JT, Lukkari-Lax E, Schulze A, Wahdan Y, Serrani M, Kroll R.Am J Obstet Gynecol. 2022 Sep 9:S0002-9378(22)00729-3. doi: 10.1016/j.ajog.2022.09.007.

Online ahead of print.

Learn more Learn more
Current use of bone turnover markers in the management of osteoporosis. PMID: 36096182

Brown JP, Don-Wauchope A, Douville P, Albert C, Vasikaran SD.Clin Biochem. 2022 Sep 9:S0009-9120(22)00204-1. doi: 10.1016/j.clinbiochem.2022.09.002.

Online ahead of print.

Learn more Learn more
Diabetes mellitus and the benefit of antiresorptive therapy on fracture risk. PMID: 36065588

Eastell R, Vittinghoff E, Lui LY, Ewing SK, Schwartz AV, Bauer DC, Black DM, Bouxsein ML.J Bone Miner Res. 2022 Sep 6. doi: 10.1002/jbmr.4697.

Online ahead of print.

Learn more Learn more
Vitamin D supplements and prevalent overactive bladder in women from midlife through older ages. PMID: 36166726

Vaughan CP, Markland AD, Huang AJ, Tangpricha V, Grodstein F.Menopause. 2022 Sep 27. doi: 10.1097/GME.0000000000002077.

Online ahead of print.

Learn more Learn more
Opinion and Special Article: The Need for Specialized Training in Women’s Neurology. PMID: 36180236

LaHue SC, Paolini S, Waters JFR, O’Neal MA.Neurology. 2022 Sep 30:10.1212/WNL.0000000000201451. doi: 10.1212/WNL.0000000000201451.

Online ahead of print.

Learn more Learn more
Working Conditions In Women With Multiple Pregnancy, The Impact On Preterm Birth And Adherence To Guidelines – A Prospective Cohort Study. PMID: 36379267

Van Beukering MDM, Van Melick MJGJ, Duijnhoven RG, Schuit E, Liem SL, Frings-Dresen MHW, Van de Wetering AJP, Spaanderman MEA, Kok M, Mol BW.Am J Obstet Gynecol. 2022 Nov 12:S0002-9378(22)02169-X. doi: 10.1016/j.ajog.2022.11.1281.

Online ahead of print.

Learn more Learn more
Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel. PMID: 36379951

Guedalia J, Lipschuetz M, Calderon-Margalit R, Cohen SM, Goldman-Wohl D, Kaminer T, Melul E, Shefer G, Sompolinsky Y, Walfisch A, Yagel S, Beharier O.Nat Commun. 2022 Nov 15;13(1):6961. doi: 10.1038/s41467-022-34605-x.

Learn more Learn more
Use of Family History of cardiovascular disease or chronic hypertension to better identify who needs postpartum cardiovascular risk screening. PMID: 36640863

Ackerman-Banks CM, Pudwell J, Lundsberg L, Lipkind HS, Smith GN.
Am J Obstet Gynecol MFM. 2023 Jan 11:100850. doi: 10.1016/j.ajogmf.2022.100850.

Online ahead of print.

Learn more Learn more
Outcomes and management of pregnancy and puerperal group A streptococcal infections: A systematic review. PMID: 36636775

Harris K, Proctor LK, Shinar S, Philippopoulos E, Yudin MH, Murphy KE.
Acta Obstet Gynecol Scand. 2023 Jan 12. doi: 10.1111/aogs.14500.

Online ahead of print.

Learn more Learn more
Endometrioma increases the risk of antibiotic treatment failure and surgical intervention in patients with pelvic inflammatory disease. PMID: 36774977

Shats M, Bart Y, Burke YZ, Cohen SB, Zolti M, Zajicek M, Mashiach R, Berkowitz E, Elizur SE.
Fertil Steril. 2023 Feb 10:S0015-0282(23)00132-2. doi: 10.1016/j.fertnstert.2023.02.004.

Online ahead of print.

Learn more Learn more
Inherited mutations affecting the SRCAP complex are central in moderate-penetrance predisposition to uterine leiomyomas. PMID: 36773604

Välimäki N, Jokinen V, Cajuso T, Kuisma H, Taira A, Dagnaud O, Ilves S, Kaukomaa J, Pasanen A, Palin K, Heikinheimo O, Bützow R, Aaltonen LA, Karhu A.
Am J Hum Genet. 2023 Feb 8:S0002-9297(23)00009-5. doi: 10.1016/j.ajhg.2023.01.009.

Online ahead of print.

Learn more Learn more
Pregnancy Complications and Long-Term Mortality in a Diverse Cohort. PMID: 36883452

Hinkle SN, Schisterman EF, Liu D, Pollack AZ, Yeung EH, Mumford SL, Grantz KL, Qiao Y, Perkins NJ, Mills JL, Mendola P, Zhang C.
Circulation. 2023 Mar 8. doi: 10.1161/CIRCULATIONAHA.122.062177. Online ahead of print.

Learn more Learn more
The Danish Newborn Standard and the Intergrowth Newborn Standard: A nationwide register-based cohort study. PMID: 36907534

Hansen DN, Kahr HS, Torp-Pedersen C, Feifel J, Uldbjerg N, Sinding M, Sørensen A.
Am J Obstet Gynecol. 2023 Mar 10:S0002-9378(23)00150-3. doi: 10.1016/j.ajog.2023.02.030. Online ahead of print.

Learn more Learn more
Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia. PMID: 37023446

Suzuki Y, Chen L, Hou JY, St Clair CM, Khoury-Collado F, de Meritens AB, Matsuo K, Melamed A, Hershman DL, Wright JD.
Obstet Gynecol. 2023 Apr 6. doi: 10.1097/AOG.0000000000005124. Online ahead of print.

 

Learn more Learn more
Severe maternal morbidity associated with endometriosis: a population based retrospective cohort study. PMID: 37030633

Park BY, Yao R, Rossi J, Lee AW.
Fertil Steril. 2023 Apr 6:S0015-0282(23)00277-7. doi: 10.1016/j.fertnstert.2023.03.033. Online ahead of print.

 

Learn more Learn more
Efficacy of Vaginal Estrogen for Recurrent Urinary Tract Infection Prevention in Hypoestrogenic Women. PMID: 37178856

Tan-Kim J, Shah NM, Do D, Menefee SA.
Am J Obstet Gynecol. 2023 May 11:S0002-9378(23)00309-5. doi: 10.1016/j.ajog.2023.05.002. Online ahead of print.

 

Learn more Learn more
Racial Differences in the Association of Endometriosis and Uterine Leiomyomas With the Risk of Ovarian Cancer. PMID: 37159277

Harris HR, Peres LC, Johnson CE, Guertin KA, Beeghly A, Bandera EV, Bethea TN, Joslin CE, Wu AH, Moorman PG, Ochs-Balcom HM, Petrick JL, Setiawan VW, Rosenberg L, Schildkraut JM, Myers E.
Obstet Gynecol. 2023 May 4. doi: 10.1097/AOG.0000000000005191. Online ahead of print.

 

Learn more Learn more
Adherence to Risk-Reducing Salpingo-Oophorectomy Guidelines Among Gynecologic Oncologists Compared to General Gynecologists PMID: 37308046

Blustein P, Werner SR, Uppalapati P, Leung TM, Husk GA, Pereira EB, Whyte JS, Villella JA.

Am J Obstet Gynecol. 2023 Jun 10:S0002-9378(23)00380-0. doi: 10.1016/j.ajog.2023.06.011. Online ahead of print.

PMID: 37308046

Learn more Learn more
Training and capacity building in obstetric fistula repair: A scoping review. PMID: 37306124

Chin EA, Arrowsmith S.

Int J Gynaecol Obstet. 2023 Jun 12. doi: 10.1002/ijgo.14901. Online ahead of print.

PMID: 37306124

Learn more Learn more
Risk of Adult Hypertension in Offspring From Pregnancies Complicated by Hypertension: Population-Based Estimates PMID: 37489531

Dines VA, Kattah AG, Weaver A, Vaughan LE, Chamberlain AM, Bielinski SJ, Mielke M, Garovic V.

Hypertension. 2023 Jul 25. doi: 10.1161/HYPERTENSIONAHA.123.20282. Online ahead of print.

PMID: 37489531

Learn more Learn more
Adverse pregnancy outcomes and risk of type 2 diabetes in postmenopausal women PMID: 37490991

Zhu K, Wactawski-Wende J, Mendola P, Parikh NI, Lamonte MJ, Barnabei VM, Hageman Blair R, Manson JE, Liu S, Wang M, Wild RA, Shadyab AH, Van Horn L, Leblanc ES, Sinkey R, Schnatz PF, Saquib N, Mu L.

Am J Obstet Gynecol. 2023 Jul 23:S0002-9378(23)00502-1. doi: 10.1016/j.ajog.2023.07.030. Online ahead of print.

PMID: 37490991

Learn more Learn more
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC) PMID: 37572987

Loibl S, Azim HA Jr, Bachelot T, Berveiller P, Bosch A, Cardonick E, Denkert C, Halaska MJ, Hoeltzenbein M, Johansson ALV, Maggen C, Markert UR, Peccatori F, Poortmans P, Saloustros E, Saura C, Schmid P, Stamatakis E, van den Heuvel-Eibrink M, van Gerwen M, Vandecaveye V, Pentheroudakis G, Curigliano G, Amant F.

Ann Oncol. 2023 Aug 9:S0923-7534(23)00798-6. doi: 10.1016/j.annonc.2023.08.001. Online ahead of print.

PMID: 37572987

Learn more Learn more
The impact of different growth charts on birthweight prediction: obstetric ultrasound versus magnetic resonance imaging PMID: 37574047

Badr DA, Cannie MM, Kadji C, Kang X, Carlin A, Jani JC.

Am J Obstet Gynecol MFM. 2023 Aug 11:101123. doi: 10.1016/j.ajogmf.2023.101123. Online ahead of print.

PMID: 37574047

Learn more Learn more
Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data PMID: 37682914

Xu X, Chen L, Nunez-Smith M, Clark M, Wright JD.

PLoS One. 2023 Sep 8;18(9):e0289692. doi: 10.1371/journal.pone.0289692. eCollection 2023.

Learn more Learn more
Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia: ACOG Clinical Consensus No. 5 PMID: 37590985

[No authors listed]

Obstet Gynecol. 2023 Sep 1;142(3):735-744. doi: 10.1097/AOG.0000000000005297.

Learn more Learn more
Botulinum Toxin for the Management of Pelvic Floor Tension Myalgia and Persistent Pelvic Pain: A Systematic Review and Meta-analysis PMID: 37797336

Knapman BL, Li FG, Deans R, Nesbitt-Hawes E, Maheux-Lacroix S, Abbott J.

Obstet Gynecol. 2023 Oct 5. doi: 10.1097/AOG.0000000000005388. Online ahead of print.

PMID: 37797336

Learn more Learn more
National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis PMID: 37805217

Ohuma EO, Moller AB, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, Okwaraji YB, Mahanani WR, Johansson EW, Lavin T, Fernandez DE, Domínguez GG, de Costa A, Cresswell JA, Krasevec J, Lawn JE, Blencowe H, Requejo J, Moran AC.

Lancet. 2023 Oct 7;402(10409):1261-1271. doi: 10.1016/S0140-6736(23)00878-4.

PMID: 37805217

Learn more Learn more
Self-Sampling for Human Papillomavirus Testing: Acceptability in a U.S. Safety Net Health System PMID: 37935320

Parker SL, Amboree TL, Bulsara S, Daheri M, Anderson ML, Hilsenbeck SG, Jibaja-Weiss ML, Zare M, Schmeler KM, Deshmukh AA, Chiao EY, Scheurer ME, Montealegre JR.

Am J Prev Med. 2023 Nov 5:S0749-3797(23)00441-5. doi: 10.1016/j.amepre.2023.10.020. Online ahead of print.

PMID: 37935320

Learn more Learn more
Effects of different insulin sensitisers in the management of polycystic ovary syndrome: A systematic review and meta-analysis PMID: 37933831

Melin JM, Forslund M, Alesi SJ, Piltonen T, Romualdi D, Spritzer PM, Tay CT, Pena AS, Witchel SF, Mousa A, Teede HJ.

Clin Endocrinol (Oxf). 2023 Nov 7. doi: 10.1111/cen.14983. Online ahead of print.

PMID: 37933831

Learn more Learn more
Risk of Thrombosis and Bleeding in Gynecologic Non-Cancer Surgery: Systematic Review and Meta-Analysis PMID:

Lavikainen LI, Guyatt GH, Kalliala IEJ, Cartwright R, Luomaranta AL, Vernooij RWM, Tähtinen RM, Najafabadi BT, Singh T; ROTBIGGS Investigators; Pourjamal N, Oksjoki SM, Khamani N, Karjalainen PK, Joronen KM, Izett-Kay ML, Haukka J, Halme ALE, Ge FZ, Galambosi PJ, Devereaux PJ, Cárdenas JL, Couban RJ, Aro KM, Aaltonen RL, Tikkinen KAO.

Am J Obstet Gynecol. 2023 Dec 8:S0002-9378(23)02117-8. doi: 10.1016/j.ajog.2023.11.1255. Online ahead of print.

Learn more Learn more
Urinary incontinence associates with poor work ability in middle-aged women: A Northern Finland Birth cohort 1966 study PMID: 38037668

Salo H, Mäkelä-Kaikkonen J, Sova H, Piltonen T, Laru J, Ala-Mursula L, Rossi HR.

Acta Obstet Gynecol Scand. 2023 Dec 1. doi: 10.1111/aogs.14743. Online ahead of print.

PMID: 38037668

Learn more Learn more
Abnormal Uterine Bleeding Diagnoses and Care following COVID-19 Vaccination PMID: 38219855

Brooks N, Irving SA, Kauffman TL, Vesco KK, Slaughter M, Smith N, Tepper NK, Olson CK, Weintraub ES, Naleway AL; Vaccine Safety Datalink Menstrual Irregularities Workgroup.

Am J Obstet Gynecol. 2024 Jan 12:S0002-9378(24)00014-0. doi: 10.1016/j.ajog.2024.01.006. Online ahead of print.

PMID: 38219855

Learn more Learn more
Urinary Incontinence in Midlife According to Weight Changes Across and After Childbearing PMID: 38214717

Taastrøm K, Kjeldsen AC, Hjorth S, Gommesen D, Axelsen SM, Nohr EA.

Int Urogynecol J. 2024 Jan 12. doi: 10.1007/s00192-023-05713-z. Online ahead of print.

PMID: 38214717

Learn more Learn more
Guideline No. 447: Diagnosis and Management of Endometrial Polyps PMID: 38325734

Guideline No. 447: Diagnosis and Management of Endometrial Polyps.

Bougie O, Randle E, Thurston J, Magee B, Warshafsky C, Rittenberg D.

J Obstet Gynaecol Can. 2024 Feb 5:102402. doi: 10.1016/j.jogc.2024.102402. Online ahead of print.

PMID: 38325734

Learn more Learn more
Associations between race and ethnicity and perioperative outcomes among women undergoing hysterectomy for adenomyosis PMID: 38342374

Associations between race and ethnicity and perioperative outcomes among women undergoing hysterectomy for adenomyosis.

Meyer R, Maxey C, Hamilton K, Nasseri Y, Barnajian M, Levin G, Truong MD, Wright KN, Siedhoff MT.

Fertil Steril. 2024 Feb 9:S0015-0282(24)00084-0. doi: 10.1016/j.fertnstert.2024.02.003. Online ahead of print.

PMID: 38342374

Learn more Learn more
Association between neighbourhood poverty and ovarian reserve: the ovarian aging study PMID: 38442312

Association between neighbourhood poverty and ovarian reserve: the ovarian aging study.

Pan A, Crowder KD, Cedars MI, Bleil ME.

Menopause. 2024 Mar 5. doi: 10.1097/GME.0000000000002331. Online ahead of print.

PMID: 38442312

Learn more Learn more
Birth Weights at Term Have Increased Globally: Insights from a Systematic Review of 183 Million Births PMID:

Birth Weights at Term Have Increased Globally: Insights from a Systematic Review of 183 Million Births.

Bonanni G, Airoldi C, Berghella V.

Am J Obstet Gynecol. 2024 Mar 7:S0002-9378(24)00431-9. doi: 10.1016/j.ajog.2024.03.002. Online ahead of print.

PMID: 38460833

Learn more Learn more
Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy № 941

Chan, Leslie N. MD; et al (Obstetrics & Gynecology 142(1):p 160-169, July 2023. DOI: 10.1097/AOG.0000000000005236) evaluated the effect of risk-reducing salpingo-oophorectomy (RRSO) on change in bone mineral density (BMD) in women aged 34–50 years with pathogenic variants in BRCA1 or BRCA2 (BRCA1/2) using The PROSper (Prospective Research of Outcomes after Salpingo-oophorectomy) study, a prospective cohort of women aged 34–50 years with BRCA1 or two germline pathogenic variants of 100 PROSper participants, 91 obtained DXA scans (RRSO group: 40; non-RRSO group: 51).

The authors concluded that women with pathogenic variants in BRCA1/2 who undergo RRSO before the age of 50 years have greater bone loss after surgery that is clinically significant when compared with those who retain their ovaries. Hormone use mitigates, but does not eliminate, bone loss after RRSO. These results suggest that women who undergo RRSO may benefit from routine screening for BMD changes to identify opportunities for prevention and treatment of bone loss.

Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk № 939

Maria Sund, et al (Breast Cancer Research and Treatment volume 198, pages361–368 (2023) ) investigated whether the safety of local estrogen therapy in patients on adjuvant endocrine treatment using a nested case–control registry-based study in a cohort of 15,198 women diagnosed with early hormone receptor (HR)-positive breast cancer and adjuvant endocrine treatment, 1262 women died due to breast cancer and were identified as cases. Each case was matched with 10 controls. Exposure to estrogen therapy with concurrent use of aromatase inhibitors (AIs), tamoxifen, or both sequentially, was compared between cases and controls.

No statistically significant difference in breast cancer mortality risk was seen in patients with exposure to estrogen therapy concurrent to endocrine treatment, neither in short-term or in long-term estrogen therapy use.

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial № 938

Neal-Perry, et al published results of a RCT evaluating the “Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause” over 52 weeks (Obstetrics & Gynecology ():10.1097/AOG.0000000000005114, March 9, 2023. | DOI: 0.1097/AOG.0000000000005114). A total of 1,830 participants were randomized and took one or more medication dose (July 2019–January 2022). Treatment-emergent adverse events occurred in 64.1% (391/610) of the placebo group, 67.9% (415/611) of the fezolinetant 30-mg group, and 63.9% (389/609) of the fezolinetant 45-mg group. Treatment-emergent adverse events leading to discontinuation were similar across groups (placebo, 26/610 [4.3%]; fezolinetant 30 mg, 34/611 [5.6%]; fezolinetant 45 mg, 28/609 [4.6%]). Endometrial safety was assessed in 599 participants. In the fezolinetant 45-mg group, 1 of 203 participants had endometrial hyperplasia (0.5%; upper limit of one-sided 95% CI 2.3%); there were no cases in the placebo (0/186) or fezolinetant 30 mg (0/210) group.

Endometrial malignancy occurred in 1 of 210 in the fezolinetant 30-mg group (0.5%; 95% CI 2.2%) with no cases in the other groups. Liver enzyme elevations more than three times the upper limit of normal occurred in 6 of 583 placebo, 8 of 590 fezolinetant 30 mg, and 12 of 589 fezolinetant 45 mg participants; no Hy's law cases were reported (ie, no severe drug-induced liver injury with alanine aminotransferase or aspartate aminotransferase more than three times the upper limit of normal and total bilirubin more than two times the upper limit of normal, with no elevation of alkaline phosphatase and no other reason to explain the combination). Changes in BMD and trabecular bone score were similar across groups. The authors concluded that this phase 3 study confirm the 52-week safety and tolerability of fezolinetant and support its continued development.

Relation between adenomyosis and elastographic characteristics of the cervix № 937

A Xholli et al (Human Reproduction, dead014, https://doi.org/10.1093/humrep/dead014) Published:03 March 2023

Analysed whether there is a possible etiologic link between cervical stiffness and adenomyosis and observed that Women with adenomyosis have a stiffer internal cervical os than those without adenomyosis. A cross-sectional study on 275 women was performed between 1 February and 31 July 2022.

Among the participants, 103 were and 172 women were not affected by adenomyosis as evaluated by ultrasonography. General and clinical characteristic of the patients were collected. Strain elastography was used to document tissue  stiffness at different regions of interest of the cervix, i.e. the internal cervical os the middle cervical canal, the anterior and the posterior cervical compartment. Tissue stiffness was expressed as a colour score from 0.1 = blue/violet (high stiffness) to 3.0 = red (low stiffness). Simple and multiple logistic regression analyses were used to evaluate the relation between the presence of adenomyosis, as the dependent variable, and independent factors. Women with adenomyosis had a higher prevalence (P = 0.0001) and intensity (P = 0.0001) of pain during menses, between menses and at intercourse compared to control. The internal cervical os colour score was lower (higher stiffness) in women with adenomyosis (0.55 ± 0.29 versus 0.67 ± 0.26; P = 0.001) and the middle cervical canal/internal cervical os colour score ratio was greater (3.32 ± 4.36 versus 2.59 ± 4.99; P = 0.008), compared to controls. Upon logistic regression modelling  (R 2  = 0.077), the internal cervical os stiffness was an independent factor related to adenomyosis (odds ratio (OR) 0.220, 95% CI 0.077, 0.627; P = 0.005) along with age (P = 0.005) and the use of gonadal steroid therapies (P = 0.002). We obtained the same results using a different logistic regression model (R 2  = 0.069), by substituting the internal cervical os stiffness with the ratio of the middle cervical canal/internal cervical os stiffness (OR 1.157, 95% CI 1.024, 1.309; P = 0.019).

Attenuated cognitive functioning decades after preeclampsia № 936
Alers et al ( : American Journal of Obstetrics and Gynecology pré-proof in press) aimed to determine the impact of preeclampsia on perceived maternal cognitive functioning decades after pregnancy.This study is part of a cross-sectional case control study named Queen of Hearts, a collaboration study of five tertiary referral centers within the Netherlands investigating long-term effects of preeclampsia.This study included 1036 women with a history of preeclampsia and 527 women with normotensive pregnancies. Regarding overall executive function, 23.2% (95%-confidence interval 19.0 to 28.1%) of women experienced clinically significant attenuation after preeclampsia compared to 2.2% (95%- confidence interval 0.8 to 6.0%) of controls just after childbirth; adjusted relative risk of 9.20 (95%-confidence interval 3.33 to 25.38). Group differences diminished yet remained statistically significant at least 19 years postpartum.Regardless of a history of preeclampsia, women with lower educational attainment, mood or anxiety disorders, or obesity were especially at risk Neither severity of preeclampsia, multiple gestation, method of delivery, preterm birth, nor perinatal death related to overall executive function.ConclusionAfter preeclampsia, women were nine times more likely to experience clinical attenuation of higher-order cognitive functions as compared to after normotensive pregnancy. Despite overall steady improvement, elevated risks persisted over decades after childbirth.
BCAA insufficiency leads to premature ovarian insufficiency via ceramide-induced elevation of ROS № 935

Guo X, et al (EMBO Mol Med. 2023 Feb 27:e17450. doi: 10.15252/emmm.202317450. Epub ahead of print. PMID: 36847712.) studied POI in a mouse model. Metabolomics analysis on serum and identified branch-chain amino acid (BCAA) insufficiency leads to premature ovarian insufficiency via ceramide-induced elevation of ROS. Since the major causes of Premature ovarian insufficiency (POI remain unknown. Many clinical studies have shown that POI patients are generally underweight, indicating a potential correlation between POI and metabolic disorders. To understand the pathogenesis of POI, they performed metabolomics analysis on serum and identified branch-chain amino acid (BCAA) insufficiency-related metabolic disorders in two independent cohorts from two clinics. A low BCAA diet phenotypically reproduced the metabolic, endocrine, ovarian, and reproductive changes of POI in young C57BL/6J mice. A mechanism study revealed that the BCAA insufficiency-induced POI is associated with abnormal activation of the ceramide-reactive oxygen species (ROS) axis and consequent impairment of ovarian granulosa cell function. Significantly, the dietary supplement of BCAA prevented the development of ROS-induced POI in female mice. The results of this pathogenic study will lead to the development of specific therapies for PO

Effects of Estradiol/Micronized Progesterone vs. Conjugated Equine Estrogens/Medroxyprogesterone Acetate on Breast Cancer Gene Expression in Healthy Postmenopausal Women № 934

Lalitkumar PGL, et al ( Int J Mol Sci. 2023 Feb 18;24(4):4123. doi: 10.3390/ijms24044123. PMID: 36835533; PMCID: PMC9959219.) investigated whether differences in the regulation of breast cancer-related gene expression could provide some explanation why estradiol (E 2 )/natural progesterone (P) confers less breast cancer risk compared with conjugated equine estrogens (CEE)/synthetic progestogens. This study is a subset of a monocentric, 2-way, open observer-blinded, phase 4 randomized controlled trial on healthy postmenopausal women with climacteric symptoms (ClinicalTrials.gov; EUCTR-2005/001016-51). Study medication was two 28-day cycles of sequential hormone treatment with oral 0.625 mg CEE and 5 mg of oral medroxyprogesterone acetate (MPA) or 1.5 mg E 2  as percutaneous gel/day with the addition of 200 mg oral micronized P. MPA and P were added days 15-28/cycle. Material from two core-needle breast biopsies in 15 women in each group was subject to quantitative PCR (Q-PCR). The primary endpoint was a change in breast carcinoma development gene expression. In the first eight consecutive women, RNA was extracted at baseline and after two months of treatment and subjected to microarray for 28856 genes and Ingenuity Pathways Analysis (IPA) to identify risk factor genes. Microarray analysis showed 3272 genes regulated with a fold-change of >±1.4. IPA showed 225 genes belonging to mammary-tumor development function: 198 for CEE/MPA vs. 34 for E 2 /P. Sixteen genes involved in mammary tumor inclination were subject to Q-PCR, inclining the CEE/MPA group towards an increased risk for breast carcinoma compared to the E 2 /P group at a very high significance level (p = 3.1 × 10 -8 , z-score 1.94). The combination of E 2 /P affected breast cancer-related genes much less than CEE/MPA.

Menopause and its Effect on Voice № 932

Ravi Shankar et al Indian J Otolaryngol Head Neck Surg2022 Dec;74(Suppl 3):5524-5530.DOI: 10.1007/s12070-021-02870-9)Evaluated the impact of menopause on voice quality using cross-sectional study (n=50 postmenopausal females as cases and 50 premenopausal females controls), of women who underwent biochemical analysis (thyroid function tests, estrogen levels, progesterone levels) and voice analysis using the VAUGHMI voice analyser software.The postmenopausal females had a poorer voice quality than the premenopausal females (Total score 1.62 vs 2.48, p < 0.001). There was a significant difference between the fundamental frequency and pitch and perturbation in frequency of the postmenopausal females as compared to premenopausal females. The difference in the perturbation in the intensity of the voice was not significant. No linear correlation could be established between the voice quality and oestrogen or progesterone levels but the intergroup variation of the two parameters was significant. The premenopausal females have better voice quality than postmenopausal females. The relationship between hormonal level and voice quality couldn't be established.Further studies are required to assess the relation of hormone levels & voice quality with the possibility of exploring voice cosmesis.

Association of Vaginal Estradiol Tablet With Serum Estrogen Levels in Women Who Are Postmenopausal: Secondary Analysis of a Randomized Clinical Trial № 926

Caroline M. Mitchell et al compare serum estrogen concentrations with the use of vaginal estrogen, 10 μg, tablet vs placebo in women who are postmenopausal. (JAMA Netw Open.
2022 Nov 1;5(11):e2241743. doi: 10.1001/jamanetworkopen.2022.41743.) in a secondary, post hoc analysis of data from a randomized clinical trial of treatment for moderate to
severe genitourinary syndrome in women who are postmenopausal. In this post hoc analysis, baseline and week 12 serum estradiol, estrone, and sex hormone-binding globulin
(SHBG) concentrations were measured by a chemiluminescent assay. A total of 174 women, mean (SD) age 61 (4) years, were included. Those in the estrogen group (n = 88) were more likely to have higher geometric mean (SD) week 12 serum estradiol concentrations (4.3 [2.2 pg/mL]) than those in the placebo group (n = 86) (3.5 [2.1] pg/mL) (P = .01). Adjusted for pretreatment hormone concentrations, age, clinical site, and body mass index, assignment to the estrogen vs placebo treatment group was significantly associated with higher week 12 estradiol concentrations (23.8% difference; 95% CI, 6.9%-43.3%). Most (121 of 174 [69.5%]) participants had enrollment serum estradiol concentrations higher than 2.7 pg/mL. Of women starting treatment at estradiol levels lower than or equal to 2.7 pg/mL, 38.1% (8 of 21) in the estrogen group and 34.4% (11 of 32) in the placebo group had estradiol concentrations higher than 2.7 pg/mL after 12 weeks of study participation (P = .78). Treatment assignment was not associated with week 12 estrone or SHBG concentrations.

Conclusions and relevance: In this secondary analysis of a randomized clinical trial, a significant, although small, increase in serum estradiol levels was noted after 12 weeks of vaginal estrogen administration. The clinical relevance of this small increase is uncertain.

Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial № 925

Ann-Sophie Page et al (BJOG 2022 Nov 8 DOI: 10.1111/1471-0528.17335) assessed whether CO 2- laser treatment is more effective than sham application in relieving the
Most Bothersome Symptom (MBS) in women with Genitourinary Syndrome of Menopause (GSM) using a Single center, sham controlled, double-blind, randomised trial. All participants eventually received three consecutive laser and three consecutive sham applications, either first laser followed by sham, or conversely. The authors Conclusions were that In women with GSM, the treatment response 12 weeks after laser application was comparable to that of sham applications. There were neither obvious differences for secondary outcomes. No serious adverse events were reported.

Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease № 924

Rocca et al (JAMA Netw Open 2022 Oct 3;5(10):e2238663. doi: 10.1001/jamanetworkopen.2022.38663) assesed the whether women who underwent premenopausal bilateral oophorectomy were at increased risk of parkinsonism and Parkinson Disease (PD) and whether the associations varied by age at oophorectomy and by receipt of estrogen replacement therapy using combined cohort studies (the Mayo Clinic Cohort Study of Oophorectomy and Aging 1 and 2, which were based on the Rochester Epidemiology Project medical records-linkage system), comprising  5499 women  of those, 2750 women underwent bilateral oophorectomy for a benign indication before spontaneous menopause between January 1, 1950, and December 31, 2007 (oophorectomy cohort), and 2749 age-matched women who did not undergo bilateral oophorectomy were randomly sampled from the general population (reference cohort). Data were analyzed from March 1 to April 30, 2022. The date of oophorectomy was considered the index date for both groups.

Exposures: Medical record documentation of bilateral oophorectomy abstracted from a medical records-linkage system (Rochester Epidemiology Project).

Main outcomes and measures: Incidence and risk of parkinsonism or PD, with diagnoses confirmed by in-person examination or medical record review.

Results: Among 5499 participants (median [IQR] age, 45.0 [40.0-48.0] years; 5312 [96.6%] White), 2750 women (2679 White [97.4%]) underwent bilateral oophorectomy at a median age of 45.0 years (IQR, 40.0-48.0 years), and 2749 women (2633 White [95.8%]) with a median age of 45.0 years (IQR, 40.0-48.0 years) at the index date were included in the reference cohort. Bilateral oophorectomy was associated with an increased risk of parkinsonism overall (hazard ratio [HR], 1.59; 95% CI, 1.02-2.46) and in women younger than 43 years at oophorectomy (HR, 7.67; 95% CI, 1.77-33.27). There was a pattern of increasing risk with younger age at the time of oophorectomy using 4 age strata (≥50 years: HR, 1.43 [95% CI, 0.50-4.15]; 46-49 years: HR, 1.55 [95% CI, 0.79-3.07]; 40-45 years: HR, 1.36 [95% CI, 0.64-2.89]; <40 years: HR, 8.82 [95% CI, 1.08-72.00]; P = .02 for trend). The number needed to harm was 53 women overall and 27 women younger than 43 years at the time of oophorectomy. Bilateral oophorectomy was also associated with an increased risk of PD in women younger than 43 years at oophorectomy (HR, 5.00; 95% CI, 1.10-22.70), with a number needed to harm of 48 women. Among women who underwent oophorectomy at 45 years and younger, the risk was lower in women who received estrogen after the procedure and through age 50 years compared with women who did not. For parkinsonism, the HRs were 1.72 (95% CI, 0.54-5.53) vs 2.05 (95% CI, 0.80-5.23); for PD, the HRs were 1.53 (95% CI, 0.29-8.23) vs 2.75 (95% CI, 0.84-9.04). However, the differences were not significant.

Conclusions and relevance: In this study, premenopausal women who underwent bilateral oophorectomy before age 43 years had an increased risk of parkinsonism and PD compared with women who did not undergo bilateral oophorectomy. These findings suggest that a reduction in the practice of prophylactic bilateral oophorectomy in premenopausal women at average risk of ovarian cancer may have substantial benefit for reducing the risk of parkinsonism and PD.

Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study № 923

Søren Cold et al (J Natl Cancer Inst. 2022 Jul 20;djac112. doi: 10.1093/jnci/djac112. ) studied longitudinally a national cohort of postmenopausal women, diagnosed 1997-2004 with early-stage invasive estrogen receptor-positive nonmetastatic breast cancer (BC), who received no treatment or 5 years of adjuvant endocrine therapy. Some women suffering from genitourinary syndrome were treated with vaginal estrogen therapy (VET) or menopausal hormone therapy (MHT). The authors ascertained prescription data on VET or MHT, from a national prescription registry and evaluated mortality and risk of recurrence.

Results: Among 8461 women who had not received VET or MHT before BC diagnosis, 1957 and 133 used VET and MHT, respectively, after diagnosis. Median follow-up was 9.8 years for recurrence and 15.2 years for mortality.
The adjusted relative risk of recurrence was 1.08 (95% confidence interval [CI] = 0.89 to 1.32) for VET (1.39 [95% CI = 1.04 to 1.85 in the subgroup receiving adjuvant aromatase inhibitors]) and 1.05 (95% CI = 0.62 to 1.78) for MHT. The adjusted hazard ratios for overall mortality were 0.78 (95% CI = 0.71 to 0.87) and 0.94 (95% CI = 0.70 to 1.26) for VET and MHT, respectively.

Conclusions: In postmenopausal women treated for early-stage estrogen receptor-positive BC, neither VET nor MHT was associated with increased risk of recurrence or mortality. A subgroup analysis revealed an increased risk of recurrence, but not mortality, in patients receiving VET with adjuvant aromatase inhibitors.

Coronary artery calcium and bone mineral density by serial CTA: Does menopausal hormone therapy modify the association? № 922

Lavanya Cherukuri et al (Randomized Controlled Trial Clin Imaging. 2022 Oct;90:26-31.)

Introduction: Both osteoporosis and cardiovascular disease (CVD) increase in women after menopause. Estrogen deficiency is thought to be an underlying mechanism for both these conditions.
Methods: Healthy menopausal women (n = 374, age 42-58 years) underwent cardiac CT scans over four years as participants in the Kronos Early Estrogen Prevention Study (KEEPS), a randomized, controlled trial to Women randomized to either oral conjugated equine estrogens (o-CEE, n = 104), transdermal 17β-estradiol (t-E2, n = 119) or placebo (n-115). CAC (Agatston units, AU), and BMD (mg/cm3) were measured from thoracic vertebrae at baseline and at the 4 years of the study using validated software. ANOVA and multiple linear regression analyzed the association between incident CAC or progression of CAC and BMD among the treatment groups.
Results: At baseline 374 women, 40 participants with CAC >0 had greater decrements in BMD than the 334 participants with CAC = 0 at baseline, The average change in BMD in o-CEE group with CAC was -9.6 ± 13.3 versus -3.1 ± 19.5 in those with zero CAC, p = 0.0018. With t-E2, BMD changed by -11.7 ± 26.2 in those with CAC versus +5.7 ± 26.2 in the zero CAC group, p ≤ 0. 0001. Similarly in the 66 participants that showed progression of CAC >1, had more BMD loss, than those with stable CAC regardless of the treatment.
Conclusion: Progression of bone loss is reduced among women treated with o-CEE or t-E2. Progression of CAC is associated with greater BMD loss, a relationship that is differentially modified by t-E2 and o-CEE.

Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age № 921

Cockrum, et al (Obstetrics and gynaecology 140(3):477-487, September 2022) evaluated associations between use of seven progestogens and incident acute venous thromboembolism (VTE) among women of reproductive age, using a nested matched case–control study. They identified women aged 15–49 years from January 1, 2010, through October 8, 2018, in the IBM MarketScan databases, a nationwide sample of private insurance claims in the United States.

After exclusions, 21,405 women with incident acute VTE (case group), identified by diagnosis codes, were matched 1:5 by year of birth and index date through risk set sampling to 107,025 women without prior VTE (control group). From lowest to highest systemic dose based on a modified hierarchy, progestogens studied were levonorgestrel-releasing intrauterine device (LNG-IUD), oral norethindrone, etonogestrel implant, oral progesterone, oral medroxyprogesterone acetate, oral norethindrone acetate, and depot medroxyprogesterone acetate (DMPA). Conditional logistic regression models adjusted for 16 VTE risk factors were used to estimate odds ratios and 99% CIs for incident acute VTE associated with current progestogen use compared with nonuse. The primary analysis treated each progestogen as a binary exposure. Dose, which varied for oral formulations, and chronicity were explored separately. Significance was set at P <.01 to allow for multiple comparisons.
Current use of higher-dose progestogens was significantly associated with increased odds of VTE compared with non-use (oral norethindrone acetate: adjusted odds ratio [aOR] 3.00, 99% CI 1.96–4.59; DMPA: aOR 2.37, 99% CI 1.95–2.88; and oral medroxyprogesterone acetate: aOR 1.98, 99% CI 1.41–2.80). Current use of other progestogens was not significantly different from nonuse (LNG-IUD, etonogestrel implant, and oral progesterone) or had reduced odds of VTE (oral norethindrone). Sensitivity analyses that assessed misclassification bias supported the primary findings.
Conclusion: Among reproductive-aged women using one of seven progestogens, only use of norethindrone acetate and medroxyprogesterone acetate—considered higher-dose progestogens—was significantly associated with increased odds of incident acute VTE. The roles of progestogen type, dose, and indication for use warrant further study.

Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults № 920

Meryl S. LeBoff et al reported in the July 28, 2022 N Engl J Med 2022(; 387:299-309 DOI:10.1056/NEJMoa2202106) that Supplemental Vitamin D did not reduce Incident Fractures in Midlife and Older Adults. They tested this In an ancillary study of the Vitamin D and Omega-3 Trial (VITAL), two-by-two factorial, randomized, controlled trial that investigated whether supplemental vitamin D 3 (2000 IU per day), n−3 fatty acids (1 g per day), or both would prevent cancer and cardiovascular disease in men 50 years of age or older and women 55 years of age or older in the United States. Participants were not recruited on the basis of vitamin D deficiency, low bone mass, or osteoporosis. Incident fractures were reported by participants on annual questionnaires and adjudicated by centralized medical-record review. The primary end points were incident total, non vertebral, and hip fractures. Proportional-hazards models were used to estimate the treatment effect in intention-to-treat analyses.

Among 25,871 participants (50.6% women, they confirmed 1991 incident fractures in 1551 participants over a median follow-up of 5.3 years. Supplemental vitamin D 3 , as compared with placebo, did not have a significant effect on total fractures (which occurred in 769 of 12,927 participants in the vitamin D group and in 782 of 12,944 participants in the placebo group; hazard ratio, 0.98; 95% CI, 0.89 to 1.08; P=0.70), nonvertebral fractures (hazard ratio, 0.97; 95% CI, 0.87 to 1.07; P=0.50), or hip fractures (hazard ratio, 1.01; 95% CI, 0.70 to 1.47; P=0.96). There was no modification of the treatment effect according to baseline characteristics,
including age, sex, race or ethnic group, body-mass index, or serum 25-hydroxyvitamin D levels. There were no substantial between-group differences in adverse events as assessed in the parent trial.
The Authors concluded that Vitamin D 3 supplementation did not result in a significantly lower risk of fractures than placebo among generally healthy midlife and older adults who were not selected for vitamin D deficiency, low bone mass, or osteoporosis.

Patterns of Sexual Activity and the Development of Sexual Pain Across the Menopausal Transition № 919

Waetjen, L. Elaine et al for the Study of Women’s Health Across the Nation (SWAN) (Obstetrics & Gynecology: June 2022 – Volume 139 – Issue 6 – p 1130-1140 doi: 10.1097/AOG.0000000000004810) examined whether patterns of sexual intercourse frequency and demographic, menopausal status, genitourinary, health, and psychosocial factors are associated with developing sexual pain across the menopausal transition.

These were longitudinal analyses of questionnaire data from the SWAN Study

Of the 2,247 women with no sexual pain at baseline, 1,087 (48.4%) developed sexual pain at least “sometimes” up to 10 follow-up visits over 13 years.

There was no consistent association between prior patterns of sexual intercourse frequency and development of sexual pain. Reasons for interruptions in intercourse activity at the prior visit, including lack of interest (aHR 1.64, 95% CI 0.74–3.65) and relationship issues (aHR 0.36, 95% CI 0.04–2.88), were not associated with developing pain. Being postmenopausal using hormone therapy (aHR 3.16, 95% CI 1.46–6.85), and reported vaginal dryness (aHR 3.73, 95% CI 2.88–4.83) were most strongly associated with incident sexual pain.

Long-term and short-term declines in sexual intercourse frequency across the menopausal transition were not associated with increased hazard of developing pain with intercourse. This empirical evidence does not support the common belief that a reduction in women’s sexual frequency is responsible for their symptoms of sexual pain.

Menopausal Hormone Therapy Formulation and Breast Cancer Risk № 918

Abenhaim, Haim A et al  (Obstetrics & Gynecology: June 2022 – Volume 139 – Issue 6 – p 1103-1110 doi: 10.1097/AOG.0000000000004723) evaluated whether the increased risk of breast cancer is dependent on the formulation of menopausal hormone therapy (HT) used. They performed a population-based case–control study of women aged 50 years or older using data from the U.K. Clinical Practice Research Datalink. Women with incident cases of breast cancer were age-matched (1:10) with a control group of women with comparable follow-up time with no history of breast cancer. Exposures were classified as ever or never for the following menopausal HT formulations: bioidentical estrogens, animal-derived estrogens, micronized progesterone, and synthetic progestin. Logistic regression analyses were performed to estimate the adjusted effect of menopausal HT formulation on breast cancer risk.

Between 1995 and 2014, 43,183 cases of breast cancer were identified and matched to 431,830 women in a control group. In adjusted analyses, compared with women who never used menopausal HT, its use was associated with an increased risk of breast cancer (odds ratio [OR] 1.12, 95% CI 1.09–1.15). Compared with never users, estrogens were not associated with breast cancer (bioidentical estrogens: OR 1.04, 95% CI 1.00–1.09; animal-derived estrogens: OR 1.01, 95% CI 0.96–1.06; both: OR 0.96, 95% CI 0.89–1.03). Progestogens appeared to be differentially associated with breast cancer (micronized progesterone: OR 0.99, 95% CI 0.55–1.79; synthetic progestin: OR 1.28, 95% CI 1.22–1.35; both OR 1.31, 0.30–5.73).

Although menopausal HT use appears to be associated with an overall increased risk of breast cancer, this risk appears predominantly mediated through formulations containing synthetic progestins. When prescribing menopausal HT, micronized progesterone may be the safer progestogen to be used.

Serum follicle stimulating hormone and five-year change in adiposity in healthy postmenopausal women № 917

Lindsey J Mattick et al (J Clin Endocrinol Metab 2022 Apr 18;dgac238. doi: 10.1210/clinem/dgac238. Online ahead of print.) evaluated the potential independent role of the interrelationships of FSH and estradiol in postmenopausal adiposity changes, using a sample of 667 postmenopausal women from the Women’s Health Initiative Buffalo OsteoPerio Ancillary Study. They studied the associations of serum FSH and estradiol levels with dual x-ray absorptiometry (DXA)-derived adiposity measures via cross-sectional and longitudinal analyses (5-year follow-up).

Results: In cross-sectional analyses, FSH levels were inversely associated with all measures of adiposity in models adjusted for age, years since menopause, smoking status, pack years, and hormone therapy (HT) use; these associations were not influenced by adjustment for serum estradiol. In longitudinal analyses, the subset of women who discontinued HT over follow-up (n=242) experienced the largest increase in FSH (+33.9 mIU/mL) and decrease in estradiol (-44.3 pg/mL) and gains in all adiposity measures in unadjusted analyses. In adjusted analyses, an increase in FSH was associated with a gain in percent total body fat, total body fat mass, and subcutaneous adipose tissue.

Conclusions: While cross-sectional findings suggest that FSH is inversely associated with adiposity, the longitudinal findings suggest that greater increases in FSH were associated with greater increases in percent total body fat, total body fat mass and subcutaneous adipose tissue. Future studies are needed to provide additional insight into FSH-adiposity mechanisms in larger samples.

Hormone and receptor activator of NF-κB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women № 916

Hormones impact breast tissue proliferation. Studies investigating the associations of circulating hormone levels with mammographic breast density have reported conflicting results. Due to the limited number of studies, Rachel Mintz et al (Breast Cancer Res . 2022 Apr 14;24(1):28.DOI: 10.1186/s13058-022-01522-2) investigated the associations of hormone gene expression as well as their downstream mediators within the plasma with mammographic breast density in postmenopausal women.

They recruited postmenopausal women at their annual screening mammogram and used the NanoString nCounter platm to quantify gene expression of hormones in plasma. They measured volumetric percent density, dense volume, and non-dense volume.
They report that one unit increase in ESR1, RANK, and TNFRSF18 gene expression was associated with 8% (95% CI 0-15%, p value = 0.05), 10% (95% CI 0-20%, p value = 0.04) and % (95% CI 0-9%, p value = 0.04) higher volumetric percent density, respectively. There were no associations between gene expression of other markers and volumetric percent density. One unit increase in osteoprotegerin and PGR gene expression was associated with 12% (95% CI 4-19%, p value = 0.003) and 7% (95% CI 0-13%, p value = 0.04) lower non-dense volume, respectively.
Conclusion: These findings provide new insight on the associations of plasma hormonal and RANK pathway gene expression with mammographic breast density in postmenopausal women and require confirmation in other studies.

Dyspareunia in Women № 915

Dyspareunia (pain with intercourse) greatly affects the quality of life, libido, relationships, and self-image of the estimated 15% of women who have this condition, and evenmore so among postmenopausal women. Its prevalence is underestimated, and it is rarely treated, beacause of shyness to discuss it with health providers and low priority for clinocians.
Gross and Brbacker wrote wrote a review paper (JAMA. Published online April 18, 2022. doi:10.1001/jama.2022.4853) insisting on the importance of initiating asking questions to patients about Dyspareunia.
We reproduce also a table from this article.

Dyspareunia Categories, Common Etiologies, Evaluation Findings, and Treatment ConsiderationsAbbreviations: DHEA, dehydroepiandrosterone; GI, gastrointestinal

Genetic insights into biological mechanisms governing human ovarian ageing № 914

Katherine S Ruth et al (Nature. 2021 Aug;596(7872):393-397. doi: 10.1038/s41586-021-03779-7. Epub 2021 Aug 4.) reported
“Genetic insights into biological mechanisms governing human ovarian ageing”.

They identified 290 genetic determinants of ovarian ageing, assessed using normal variation in age at natural menopause (ANM) in about 200,000 women of European ancestry. These common alleles were associated with clinical extremes of ANM; women in the top 1% of genetic susceptibility have an equivalent risk of premature ovarian insufficiency to those carrying monogenic FMR1 premutations. The identified loci implicate a broad range of DNA damage response (DDR) processes and include loss-of-function variants in key DDR-associated genes. Integration with experimental models demonstrates that these DDR processes act across the life-course to shape the ovarian reserve and its rate of depletion. Furthermore, we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics increases fertility and extends reproductive life in mice. Causal inference analyses using the identified genetic variants indicate that extending reproductive life in women improves bone health and reduces risk of type 2 diabetes, but increases the risk of hormone-sensitive cancers. These findings provide insight into the mechanisms that govern ovarian ageing, when they act, and how they might be targeted by therapeutic approaches to extend fertility and prevent disease.

Randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density. № 913

Edgar Tapia et al (Breast Cancer Res Treat. 2021 Nov;190(1):69-78.

doi: 10.1007/s10549-021-06355-9. Epub 2021 Aug 12.) conducted a Phase II double-blind,  “randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density”. Eligible participants were randomized to receive metformin (850 mg BID, n = 76) or placebo (n = 75) for 12 months. Outcomes included breast density, assessed by fat/water MRI with change in percent breast density as the primary endpoint, anthropometric measures, and intervention feasibility.

Results: Seventy-six percent in the metformin arm and 83% in the placebo arm (p = 0.182) completed the 12-month intervention. Adherence to study agent was high with more than 80% of participants taking ≥ 80% assigned pills. The most common adverse events reported in the metformin arm were gastrointestinal in nature and subsided over time. Compared to placebo, metformin intervention led to a significant reduction in waist circumference (p < 0.001) and waist-to-hip ratio (p = 0.019). Compared to placebo, metformin did not change percent breast density and dense breast volume but led to a numerical but not significant decrease in non-dense breast volume (p = 0.070).

Association Between Laparoscopically Confirmed Endometriosis and Risk of Early Natural Menopause (ENM) № 912

Madhavi Thombre Kulkarni et al (JAMA Netw Open. 2022 Jan 4;5(1):e2144391.

doi: 10.1001/jamanetworkopen.2021.44391) reported an “Association Between Laparoscopically Confirmed Endometriosis and Risk of Early Natural Menopause (ENM)” using a large, population-based cohort study (the Nurses’ Health Study II cohort questionnaires from the 1989 to 2015).

The sample included premenopausal women aged 25- 42 years at baseline or enrollment in 1989. Cumulative follow-up rate was greater than 90%, and participants continued follow-up until the onset of ENM, age 45 years, hysterectomy, oophorectomy, cancer diagnosis, death, loss to follow-up, or end of follow-up in May 2017, whichever occurred first. Data analyses were conducted from October 26, 2020, to April 27, 2021.

During 1 508 462 person-years of follow-up, 6640 participants reported being diagnosed with endometriosis, 99 993 never reported endometriosis, and 2542 reported experiencing ENM. In the age- and calendar time-adjusted model, laparoscopically confirmed endometriosis was associated with a 50% greater risk for ENM [HR], 1.51; 95% CI, 1.30-1.74). A similar risk was observed after adjusting for race and ethnicity and time-varying anthropometric and behavioral factors (HR, 1.46; 95% CI, 1.26-1.69). With additional adjustment for reproductive factors, the HR of ENM was attenuated but significant (HR, 1.28; 95% CI, 1.10-1.48).

Conclusions and relevance: This cohort study found a risk for ENM in women with laparoscopically confirmed endometriosis. These women compared with those without endometriosis may be at a higher risk for shortened reproductive duration, particularly those who were nulliparous or never used oral contraceptives.

Age at menopause and risk of lung cancer № 911

Hsin-Fang Chung et al conducted a systematic review about “Age at menopause and risk of lung cancer” Maturitas. 2021 Nov; 153:1-10.doi: 10.1016/j.maturitas.2021.07.010. Epub 2021 Jul 21.

28 studies were included. They found that early menopause was associated with lung cancer in both cohort studies (RR 1.26, 1.10-1.41; n=6) and case-control studies (OR 1.38, 1.11-1.66; n=5). Three large cohort studies showed that the increased risk was primarily evident among smokers (RR 1.38, 1.10-1.66) but not among non-smokers (RR 1.02, 0.63-1.40). Four case-control studies found that late menopause was also associated with lung cancer (OR 1.29, 1.08-1.51); conversely, the association was mainly observed among non-smokers (OR 1.35, 1.11-1.59) but not among smokers (OR 1.05, 0.75-1.36).
In conclusion, evidence from this review indicates an increased risk of lung cancer in women who experience early menopause (≤45 years), although this risk is primarily among smokers. Large prospective cohort studies are needed to confirm the association between late menopause (≥55 years) and lung cancer risk among non-smokers.

Age at menopause in women living with HIV № 910

Clara E Van Ommen et al reported a systematic review on “Age at menopause in women living with HIV”

(Menopause  . 2021 Dec 1;28(12):1428-1436. DOI: 10.1097/GME.0000000000001871)

Their Findings were the following based on 9 studies. Across studies, the age at menopause for WLWH fell between 46 and 50 years. Five of seven studies reported that WLWH had an earlier menopausal transition than HIV negative controls/the general population. Six studies reported on the prevalence of POI or early menopause among WLWH, with all studies demonstrating an increased prevalence of both among WLWH.

Overall, they also highlighted the need for further investigation with studies that include an HIV negative control group and biochemical confirmation of menopause to better understand whether menopause truly is occurring earlier among WLWH.

Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study № 908

F Gernier et al Gynecol Oncol. 2021 Oct 11;S0090-8258(21)01419-0.

Epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study ( n = 166, with relapse-free ≥3 years after the end of treatment) investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS).

166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a blood sample and an osteodensitometry. QoL, fatigue, insomnia and mood disorders were measured with validated questionnaires and correlated to VMS. VMS and QoL were assessed according to natural menopause (NM) or surgical menopause (SM).

Results: Mean age at the survey was 62 [21-83] years and stage III/IV (48%). Mean delay since the end of treatment was 6 years. Fifty-nine patients (36%) had surgical menopause (SM). Half of patients reported vasomotor symptoms (VMS). Seventy-two percent of EOCS with SM had VMS compared to 41% with natural menopause (NM) (P < .001). VMS were not associated with poor global QoL, fatigue, insomnia or mood disorders. Two-thirds of EOCS reported a decrease in libido. Patients with SM showed a greater decrease in libido than NM (P < .02). Fourteen percent of them had osteoporosis and 50% osteopenia. Among the 85 patients with VMS, 80 did not receive HRT after cancer treatment. At the time of the survey, only 7 (4%) patients were receiving hormone replacement therapy (HRT).

The authors’ Conclusions: VMS and sexual disorders are frequently reported by EOCS, particularly among patients with SM. Most EOCS with menopausal symptoms could benefit from HRT to improve these symptoms.

Age at menopause and risk of lung cancer: A systematic review and meta-analysis № 907

Hsin-Fang Chung et al Maturitas 2021 Nov;153:1-10.

doi: 10.1016/j.maturitas.2021.07.010

Previous reviews have found that menstrual and reproductive factors are associated with lung cancer risk, but evidence on a possible association with age at menopause is inconsistent. This review aimed to determine the association of early and late menopause with lung cancer risk. Publications were reviewed and obtained through PubMed, EMBASE and Scopus database search up to March 2021. The pooled relative risks (RRs) or odds ratios (ORs) and corresponding 95% CIs were estimated using a random-effects meta-analysis. Twenty-eight studies were included in at least one meta-analysis, of age at menopause (lowest vs highest; n=26), early menopause (≤45 vs ≥50/51 years or middle; n=11), late menopause (≥55 vs <50 years or middle; n=6), or continuous (per additional year; n=6). We found that early menopause was associated with lung cancer in both cohort studies (RR 1.26, 1.10-1.41; n=6) and case-control studies (OR 1.38, 1.11-1.66; n=5). Three large cohort studies showed that the increased risk was primarily evident among smokers (RR 1.38, 1.10-1.66) but not among non-smokers (RR 1.02, 0.63-1.40). Four case-control studies found that late menopause was also associated with lung cancer (OR 1.29, 1.08-1.51); conversely, the association was mainly observed among non-smokers (OR 1.35, 1.11-1.59) but not among smokers (OR 1.05, 0.75-1.36). In conclusion, evidence from this review indicates an increased risk of lung cancer in women who experience early menopause (≤45 years), although this risk is primarily among smokers. Large prospective cohort studies are needed to confirm the association between late menopause (≥55 years) and lung cancer risk among non-smokers. PROSPERO registration: CRD42020205429.

Menopause Per se Is Associated with Coronary Artery Calcium Score: Results from the ELSA-Brasil № 906

Marília I H Fonseca 1 et al  J Womens Health (Larchmt). 2021 Sep 14.  doi:  0.1089/jwh.2021.0182. Online ahead of print.

Background: Menopause and aging deteriorate the metabolic profile, but little is known about how they independently contribute to structural changes in coronary arteries. We compared a broad cardiometabolic risk profile of women according to their menopausal status and investigated if menopause per se is associated with presence of coronary artery calcium (CAC) in the ELSA-Brasil. Materials and Methods: All participants, except perimenopausal women, who had menopause <40 years or from non-natural causes or reported use of hormone therapy were included. Sample was stratified according to menopause and age categories (premenopause ≤45 years, premenopause >45 years, and postmenopause); their clinical profile and computed tomography-determined CAC were compared using Kruskal-Wallis and chi squared test for frequencies. Associations of CAC (binary variable) with menopause categories adjusted for traditional and nontraditional covariables were tested using logistic regression. Results: From 2,047 participants 51 ± 9 years of age, 1,175 were premenopausal (702 ≤ 45 years) and 872 were postmenopausal women. Mean values of anthropometric variables, blood pressure, lipid and glucose parameters, branched-chain amino acids (BCAA), and homeosthasis model assessment (HOMA-IR), as well as frequencies of morbidities, were more favorable in premenopausal, particularly in younger ones. In crude analyses, CAC >0 was associated with triglyceride-rich lipoprotein remnants, dense low-density lipoprotein, BCAA, and other variables, but not with HOMA-IR. Menopause was independently associated with CAC >0 (odds ratios 2.37 [95% confidence interval 1.17-4.81]) when compared to the younger premenopausal group.

Conclusion: Associations of menopause with CAC, independent of traditional and nontraditional cardiovascular risk factors, suggest that hormonal decline per se may contribute to calcium deposition in coronary arteries.

Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial № 905

Fiona G Li et al JAMA 2021 Oct 12;326(14):1381-1389 evaluated the efficacy of fractional carbon dioxide laser for treatment of vaginal symptoms associated with menopause in a double-blind, randomized, sham-controlled trial with 12-month follow-up at a single tertiary referral hospital in Sydney, Australia. Enrollment commenced on September 19, 2016, with final follow-up on June 30, 2020. Participants were postmenopausal women with vaginal symptoms substantive enough to seek medical treatment. Of 232 participants approached, 85 were randomized. Three treatments using a fractional microablative carbon dioxide laser system performed 4 to 8 weeks apart, with 43 women randomized to the laser group and 42 to the sham group.

The co-primary outcomes were symptom severity assessed using a visual analog scale (VAS; range, 0-100; 0 indicates no symptoms and 100 indicates the most severe symptoms) and the Vulvovaginal Symptom Questionnaire (VSQ; range, 0-20; 0 indicates no symptoms and 20 indicates the most severe symptoms) at 12 months.

The minimal clinically important difference was specified as a 50% decrease in both VAS and VSQ severity scores. Of 85 randomized participants (mean [SD] age, 57 [8] years), 78 (91.7%) completed the 12-month follow-up. From baseline to 12 months, there was no significant difference between the carbon dioxide laser group and the sham group in change in symptom severity

Conclusions and relevance: Among women with postmenopausal vaginal symptoms, treatment with fractional carbon dioxide laser vs sham treatment did not significantly improve vaginal symptoms after 12 months.

Long-term Use of Hormone Replacement Therapy is Associated With a Lower Risk of Developing High-risk Serrated Polyps in Women № 904

Dylan E O’Sullivan  et al (J Clin Gastroenterol. 2021 Aug 18. doi: 10.1097/MCG.0000000000001606. ) reported  Data from a cross-sectional study of 1384 women undergoing screening-related colonoscopy between 2008 and 2016 were analyzed. Modified Poisson regression models with robust error variance were used to determine the relative risk (RR) of developing adenomatous polyps, serrated polyps, high-risk adenomatous polypss (HRAPs), and high-risk serrated polyps (HRSPs) associated with pregnancy, menopausal status, and the use of HRT (duration and type).

Results: Women that used HRT for ≥6 years were at a significantly lower risk of developing a [HRSP :RR: 0.53; 95% CI: 0.29-0.97]. Irrespective of the duration of use, the use of HRT that included progesterone alone or with estrogen was associated with a significantly lower risk of developing a HRSP (RR: 0.54; 95% CI: 0.30-0.95). The use HRT with progesterone for ≥6 years was associated with a nonsignificant lower risk of developing a HRSP (RR: 0.42; 95% CI: 0.17-1.04). None of the reproductive factors assessed or HRT were associated with the development of adenomatous polyps or HRAPs.

Conclusions: The results of this study suggests that the long-term use of HRT, and therapies that include progesterone are associated with a lower risk of developing HRSPs. These results could have implications for targeted screening for serrated polyps among women.

Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial № 902

Keren Shahar-Nissan et al (Lancet. 2020 Oct 10;396(10257):1070. doi: 10.1016/S0140-6736(20)32075-4.PMID: 33038969 ) aimed to investigate whether valaciclovir can prevent vertical transmission of cytomegalovirus to the fetus in pregnant women with a primary infection acquired early in pregnancy using an RCT and assigned to oral valaciclovir (8 g per day, twice daily) or placebo from enrolment until amniocentesis at 21 or 22 gestational weeks.

The final analysis included 45 patients (all singletons) in the valaciclovir group and 45 patients (43 singletons and two sets of twins) in the placebo group. In the valaciclovir group, including both first trimester and periconceptional infections, five (11%) of 45 amniocenteses were positive for cytomegalovirus, compared with 14 (30%) of 47 amniocenteses in the placebo group (p=0·027; odds ratio 0·29, 95% CI 0·09-0·90 for vertical cytomegalovirus transmission). Among participants with a primary cytomegalovirus infection during the first trimester, a positive amniocentesis for cytomegalovirus was significantly less likely in the valaciclovir group (two [11%] of 19 amniocenteses) compared with the placebo group (11 [48%] of 23 amniocenteses; p=0·020. No clinically significant adverse events were reported.

Interpretation: Valaciclovir is effective in reducing the rate of fetal cytomegalovirus infection after maternal primary infection acquired early in pregnancy. Early treatment of pregnant women with primary infection might prevent termination of pregnancies or delivery of infants with congenital cytomegalovirus.

Funding: None.

Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children № 887

Question  Is maternal antenatal corticosteroid treatment associated with mental and behavioral disorders in children?

Katri Räikkönen et al (JAMA. 2020;323(19):1924-1933. doi:10.1001/jama.2020.3937) used a population-based retrospective cohort study in Finland that included 670 097 children, exposure to maternal antenatal corticosteroid treatment, compared with nonexposure, was significantly associated with mental and behavioral disorders in children (hazard ratio, 1.33).

Meaning   These findings may help inform decisions about maternal antenatal corticosteroid treatment.

Here are some more details of the study.

Design, Setting, and Participants  Population-based retrospective cohort study using nationwide registries of all singleton live births in Finland surviving until 1 year and a within-sibpair comparison among term siblings. Children were born between January 1, 2006, and December 31, 2017, and followed up until December 31, 2017.

Exposures  Maternal antenatal corticosteroid treatment.

Main Outcomes and Measures  Primary outcome was any childhood mental and behavioral disorder diagnosed in public specialized medical care settings.

Results  Of the 674 877 singleton children born in Finland during the study period, 670 097 were eligible for analysis. The median length of follow-up was 5.8 (interquartile-range, 3.1-8.7) years. Of the 14 868 (2.22%; 46.1% female) corticosteroid treatment–exposed children, 6730 (45.27%) were born at term and 8138 (54.74%) were born preterm; of the 655 229 (97.78%; 48.9% female) nonexposed children, 634 757 (96.88%) were born at term and 20 472 (3.12%) were born preterm. Among the 241 621 eligible term-born maternal sibpairs nested within this population, 4128 (1.71%) pairs were discordant for treatment exposure. Treatment exposure, compared with nonexposure, was significantly associated with higher risk of any mental and behavioral disorder in the entire cohort of children (12.01% vs 6.45%; absolute difference, 5.56% [95% CI, 5.04%-6.19%]; adjusted hazard ratio [HR], 1.33 [95% CI, 1.26-1.41]), in term-born children (8.89% vs 6.31%; absolute difference, 2.58% [95% CI, 1.92%-3.29%]; HR, 1.47 [95% CI, 1.36-1.69]), and when sibpairs discordant for treatment exposure were compared with sibpairs concordant for nonexposure (6.56% vs 4.17% for within-sibpair differences; absolute difference, 2.40% [95% CI, 1.67%-3.21%]; HR, 1.38 [95% CI, 1.21-1.58]). In preterm-born children, the cumulative incidence rate of any mental and behavioral disorder was also significantly higher for the treatment-exposed compared with the nonexposed children, but the HR was not significant (14.59% vs 10.71%; absolute difference, 3.38% [95% CI, 2.95%-4.87%]; HR, 1.00 [95% CI, 0.92-1.09]).

Breast Cancer Risk in Postmenopausal Women With Medical History of Thyroid Disorder in the Women’s Health Initiative № 886

Chien-Hsiang Weng et al . (Thyroid
2020 Apr;30(4):519-530.  doi: 10.1089/thy.2019.0426. Epub 2020 Feb 3) conducted a prospective cohort study of multiethnic U.S. postmenopausal women aged 50 to 79 years enrolled in both clinical trial and observational study arms between 1993 and 1998 and followed up through February 28, 2017. Development of invasive breast cancer after enrollment was recorded and a history of hyper- or hypothyroidism before the diagnosis of breast cancer was identified. The effect modification by MHT in both study arms was analyzed. All statistical tests were two sided.

Results: Among a total of 134,122 women included in the study, 8137 participants developed invasive breast cancer during the follow-up period. There was a significant inverse association of invasive breast cancer among women with a history of hypothyroidism (hazard ratio [HR] 0.91,[95% CI] 0.86-0.97) and among women who had taken levothyroxine [HR 0.89, 95% CI 0.82-0.96]. Evaluating effect modification by MHT use, the inverse association between hypothyroidism treated with thyroid replacement medications and breast cancer risk was strongest in non-MHT users [HR 0.80, 95% CI 0.69-0.93]. The results did not significantly differ by race/ethnicity. Although a history of hyperthyroidism was associated with an increased risk of invasive breast cancer [HR 1.11, 95% CI 0.91-1.35], this finding did not reach statistical significance. They did not see significant differences in the breast cancer Surveillance, Epidemiology, and End Results stages, histologic types, morphologic grades, or receptor status (estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2) according to thyroid disorder status.

Conclusions: Compared with women with no history of thyroid disorder, hypothyroidism was associated with a lower risk of breast cancer. This was mainly seen among those who received thyroid replacement therapy and had never used MHT. Among the treatment options for hypothyroidism, levothyroxine had the strongest inverse association with breast cancer risk.

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. № 885

Mavaddat N et al (Breast Cancer Res. 2020 Jan 16;22(1):8. doi: 10.1186/s13058-020-1247-4.) evaluated the effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers in a multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers, followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women.
RESULTS:
There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar.
CONCLUSION:
We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.

Arterial Stiffness Accelerates Within 1 Year of the Final Menstrual Period: The SWAN Heart Study. № 884

Samargandy et al (Arterioscler Thromb Vasc Biol. 2020 Jan 23:ATVBAHA119313622. doi: 10.1161/ATVBAHA.119.313622. [Epub ahead of print]) determined whether and when women experience changes in arterial stiffness relative to the final menstrual period (FMP) and whether these changes differ between black and white midlife women studying 339 participants from the SWAN Heart Ancillary study (Study of Women’s Health Across the Nation). The interval within 1 year of FMP is a critical period for women when vascular functional alterations occur. These findings underscore the importance of more intensive lifestyle modifications in women transitioning through menopause.
Women had ≤2 carotid-femoral pulse-wave velocity (cfPWV) exams over a mean±SD of 2.3±0.5 years of follow-up. Annual percentage changes in cfPWV were estimated in 3 time segments relative to FMP and compared using piecewise linear mixed-effects models. At baseline, women were 51.1±2.8 years of age and 36% black.
Annual percentage change (95% CI) in cfPWV varied by time segments: 0.9% (-0.6% to 2.3%) for >1 year before FMP, 7.5% (4.1%-11.1%) within 1 year of FMP, and -1.0% (-2.8% to 0.8%) for >1 year after FMP. Annual percentage change in cfPWV within 1 year of FMP was significantly greater than the other 2 time segments; P<0.05 for both comparisons. Adjusting for concurrent cardiovascular disease risk factors explained part of the change estimates but did not eliminate the difference.

Black women had greater increase in cfPWV compared with white women in the first segment; P for interaction, 0.04.

The authors concluded that the interval within 1 year of FMP is a critical period for women when vascular functional alterations occur. These findings underscore the importance of more intensive lifestyle modifications in women transitioning through menopause.

At the latest San Antonio Breast cancer symposium... № 883

...(December 2019, https://www.abstractsonline.com/pp8/#!/7946/presentation/2229), Chlebowski et al presented the long-term Breast cancer outcomes from the WHI Estrogen plus Progestin and Estrogen-alone trials.

During the intervention period, with 238 incident breast cancers, CEE-alone significantly reduced breast cancer incidence (HR 0.76 95%CI 0.58, 0.98, P = 0.04). As previously reported, subgroup analyses indicated CEE-alone was particularly beneficial for women with no prior HT use (interaction P = 0.04) and women with gap time >= 5 years (interaction P = 0.01). Post-intervention, through 16.1 years of cumulative follow-up, with 520 incident breast cancers, CEE-alone use continued to significantly reduce breast cancer incidence (HR 0.77 95% CI 0.65-0.92, P = 0.005) while subgroup differences were attenuated and were no longer statistically significant.

During the intervention period, with 360 incident breast cancers, CEE plus MPA use significantly increased breast cancer incidence (HR 1.26 95% CI 1.02, 1.56, P = 0.04) with increase in breast cancer incidence greater in women with prior HT use (interaction P = 0.02) and women with gap time < 5 years (interaction P = 0.002). Post-intervention, through 18.3 years cumulative follow-up, with 1,003 incident breast cancers, CEE plus MPA continued to significantly increase breast cancer incidence (HR 1.29 95% CI 1.14, 1.47, P < 0.001) while subgroup differences were attenuated and were no longer statistically significant.
The authors Conclusions: CEE-alone and CEE plus MPA use have opposite effects on breast cancer incidence. CEE alone significantly decreases breast cancer incidence which is long term and persists over a decade after discontinuing use. CEE plus MPA use significantly increases breast cancer incidence which is long term and persists over a decade after discontinuing use. As a result of the attenuation of subgroup interactions: all postmenopausal women with prior hysterectomy using CEE-alone have the potential benefit of experiencing a reduction in breast cancer incidence while all postmenopausal women using CEE plus MPA have the potential risk of experiencing an increase in breast cancer incidence.

Honingberg et al (JAMA)... № 882

...(published online November 18, 2019 doi: https://doi.org/10.1001/jama.2019.19191) reported that both premature (before 40 years) natural and surgical menopause are associated with higher incident Cardiovascular Disease (for a composite outcome that included coronary artery disease, heart failure, aortic stenosis, mitral regurgitation, atrial fibrillation, ischemic stroke, peripheral artery disease, and venous thromboembolism.  In a cohort study that included 144 260 postmenopausal women, For natural premature menopause, the hazard ratio was 1.36; for surgical premature menopause, the hazard ratio was 1.87.